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ABSTRACT1 
 
The prevalence of milder forms of HIV-associated neurocognitive disorders 
(HAND) is rising despite combination antiretroviral therapy (cART). Efavirenz (EFV) is 
among the most commonly used antiretroviral drugs globally, but causes neurological 
symptoms that may interfere with adherence and reduce tolerability, and may have 
central nervous system (CNS) effects that contribute in part to HAND in patients on 
cART. Thus we evaluated a commonly used EFV containing regimen: EFV/zidovudine 
(AZT)/lamivudine (3TC) in murine N2a cells transfected with the human “Swedish” 
mutant form of amyloid precursor protein (SweAPP N2a cells) to assess for promotion 
of amyloid-beta (Aβ) production (Chapter 3). Treatment with EFV or the EFV containing 
regimen generated significantly increased soluble Aβ, and promoted increased β-
secretase-1 (BACE-1) expression while 3TC, AZT, or, vehicle control did not 
significantly alter these endpoints. Further, EFV or the EFV containing regimen 
promoted significantly more mitochondrial stress in SweAPP N2a cells as compared to 
3TC, AZT, or vehicle control. We next tested the EFV containing regimen in Aβ - 
producing Tg2576 mice combined or singly using clinically relevant doses. EFV or the 
EFV containing regimen promoted significantly more BACE-1 expression and soluble 
Aβ generation while 3TC, AZT, or vehicle control did not. Finally, microglial Aβ 
phagocytosis was significantly reduced by EFV or the EFV containing regimen but not 																																																								1	Portions of this abstract have been previously published (Brown LAM, et al., 2014; Jin, J, et al, 2016) 
and are utilized with permission of the publisher.1 	
 ix 
by AZT, 3TC, or vehicle control alone. These data suggest the majority of Aβ promoting 
effects of this cART regimen are dependent upon EFV as it promotes both increased 
production, and decreased clearance of Aβ peptide. 
 
Further (Chapter 4), there is evidence that neural stem cells (NSCs) can migrate 
to sites of brain injury such as those caused by inflammation and oxidative stress, which 
are pathological features of HAND. Thus, reductions in NSCs may contribute to HAND 
pathogenesis. Since the HIV non-nucleoside reverse transcriptase inhibitor EFV has 
previously been associated with cognitive deficits and promotion of oxidative stress 
pathways, we examined its effect on NSCs in vitro as well as in C57BL/6J mice. Here 
we report that EFV induced a decrease in NSC proliferation in vitro as indicated by MTT 
assay, as well as BrdU and nestin immunocytochemistry. In addition, EFV decreased 
intracellular NSC adenosine triphosphate (ATP) stores and NSC mitochondrial 
membrane potential (MMP). Further, we found that EFV promoted increased lactate 
dehydrogenase (LDH) release, activation of p38 mitogen-activated protein kinase 
(MAPK), and increased Bax expression in cultured NSCs. Moreover, EFV reduced the 
quantity of proliferating NSCs in the subventricular zone (SVZ) of C57BL/6 mice as 
suggested by BrdU, and increased apoptosis as measured by active caspase-3 
immunohistochemistry. If these in vitro and in vivo models translate to the clinical 
syndrome, then a pharmacological or cell-based therapy aimed at opposing EFV-
mediated reductions in NSC proliferation may be beneficial to prevent or treat HAND in 
patients receiving EFV. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
Human Immunodeficiency Virus (HIV) 
Human Immunodeficiency Virus (HIV) is the etiological agent causing Acquired 
Immune Deficiency Syndrome (AIDS). An estimated 35 million people are living with 
HIV worldwide, with roughly 2.4 million infected each year [1]. HIV is a retrovirus 
belonging to the lentivirus family, and it uses reverse transcriptase to transcribe RNA 
into DNA prior to incorporation into the host cell chromosome [2]. The origin of the word 
lentus means slow, referring to the slow course of disease progression associated with 
HIV infection [2, 3]. This slow progression is what leads to the wasting characteristic of 
the disease as it causes immune deficiency, neurodegeneration, and death. The 
complexity of a lentivirus, especially HIV, sets it apart from other viral genomes. Not 
only does HIV encode for the typical 3 genes of env, gag and pol, but it also has 
regulatory genes (tat, rev, nef) and auxiliary genes (vif, vpr, vp4) [4, 5]. As 
aforementioned, HIV affects the world globally; however, there are different types and 
subtypes most prevalent within a given area. HIV is divided into 2 groups: HIV-1 and 
HIV-2. HIV-2 is similar to Simian Immunodeficiency Virus, and is restricted to regions 
within West Africa [6]. HIV-1 however, is the most common type worldwide. 
 
  
	 2 
HIV Replication Cycle 
Entry of the virus into the target cell occurs when the HIV envelope protein 
gp120/gp41 binds to CD4+ immune cells, in addition to a chemokine co-receptor (CCR5 
or CXCR4) [7-9]. Viral entry and fusion aids in uncoating the viral core so as to allow 
reverse transcription and proviral synthesis [10]. Reverse transcriptase has RNA 
dependent DNA polymerase, ribonuclease (RNase)-H, and DNA dependent DNA 
polymerase functionalities, required for HIV viral transcription [11]. A key part of viral 
processing is the completion of reverse transcription in order to form a pre-integration 
complex (PIC) composed of cellular and viral components, which migrate to the 
nucleus. In the nucleus, the HIV integrase begins incorporating the viral DNA with the 
host DNA [12]. Integration of the HIV DNA is important for HIV mRNA/RNA expression; 
once integrated into the host genome, transcription can occur through the binding of the 
HIV regulatory protein Tat to the HIV trans-activation response element (TAR) [13]. 
Following, new viral RNA and viral proteins move to the cell surface to assemble into 
new immature virus forms to buds off and release. Assembly and maturation on the 
inner plasma membrane is the next step of the HIV virus. During maturation, the 
protease enzyme cleaves the structural polyprotein to form mature Gag proteins, 
resulting in the production of new infectious virions [14].  
 
HIV and the Central Nervous System (CNS) 
HIV enters the CNS early post-infection.  This viral presence in the CNS can 
result in cognitive impairment. Although the virus itself cannot infect the neurons, it is 
the indirect mechanisms that cause the neurocognitive decline [15, 16]. HIV enters the 
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CNS either by crossing the blood brain barrier (BBB) in infected lymphocytes and 
monocytes or by entering the cerebrospinal fluid (CSF) on its own resulting in 
subsequent cognitive impairment. Although the virus itself cannot infect neurons, HIV 
causes the decrease in neurocognition through various indirect mechanisms [15, 16]. 
There are two mechanisms by which HIV infects the CNS: productive and restricted 
infection. Productive infection involves host cells (monocyte-derived macrophages and 
microglia) aiding in the viral replication and transmission processes [17-20]. Conversely, 
restricted infection lies latent in a large number of undividing astrocytes as a reservoir 
[21-23]. The latency of HIV in astrocytes may be a pertinent factor in neuropathology, as 
even with adherence to a cART regimen, this form of restricted infection may elude the 
drugs [24]. Moreover, despite their non-proliferative status, latent HIV-infected cells can 
express viral proteins and neurotoxins [25, 26], and each class of therapeutic agents 
has displayed difficulty in crossing the BBB in order to efficiently interact with the virus. 
 
HIV and Alzheimer’s Disease-like Pathology  
The characterization of neurodegenerative disorders is associated with neuronal 
loss and accumulation of fibrillary materials. These characteristics are found in head 
trauma, Down Syndrome, and many other instances including Alzheimer’s disease (AD) 
[27-29]. AD is the most common type of age-associated dementia accounting for 60% to 
80% of all cases [30]. AD is characterized by age-dependent β-amyloid/beta amyloid 
(Aβ) and tau tangle accumulation, which can eventually impair an individual’s ability to 
carry out acts of daily living (ADLs). It has been hypothesized that AD will significantly 
increase among persons living with HIV [31]. Furthermore, studies have shown 
	 4 
evidence of AD-like pathologies in HIV demented patients [32-40]. Our study will 
explore beta amyloid generation accordingly. 
 
Beta Amyloid (Aβ) 
 Aβ (one of the hallmarks of AD) causes the formation of cerebral plaques prone to 
the frontal cortex and hippocampus. Aβ causes progressive neuronal loss resulting in 
the deterioration of the brain’s high and basic functionalities. Amyloid precursor protein 
(APP) is processed via two pathways: non-amyloidogenic (preventing Aβ production) or 
amyloidogenic (leading to Aβ production). In the non-amyloidogenic pathway APP is 
initially cleaved by α-secretase yielding soluble (s)APPα and α-carboxyl-terminal 
fragment (CTF). α-CTF is then cleaved by γ-secretase to form a 23-25 amino acid 
peptide (p3) precluding formation of Aβ. Conversely, in the amyloidogenic pathway, 
APP is initially cleaved by β-secretase (BACE)-1, resulting in β-CTF, and sAPPβ. β-CTF 
is then cleaved by a multi-protein γ-secretase complex to generate Aβ and γ-CTF [41]. 
Aβ42 represents about 10% of Aβ produced with a greater propensity to form neurotoxic 
oligomeric and aggregated species. Aβ40, however, is the most common form in the 
human brain [42, 43]. 
 
In addition to the accumulation of Aβ in the brain, the clearance of this protein is 
a matter to be discussed further in this research. In humans, microglia compose up to 
16% (5-12% in rodent) of the cells in CNS and account for one of the main mechanisms 
by which Aβ is cleared [44]. Microglia express receptors that promote the clearance of 
Aβ including class A scavenger receptor (SR-A), CD36 and receptor for advanced 
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glycosylation end products (RAGE) [45, 46]. In addition, microglia secrete proteolytic 
enzymes that degrade Aβ such as insulin-degrading enzyme (IDE), neprilysin (NEP), 
matrix metalloproteinase 9 (MMP9), and plasminogen [47, 48]. This suggests the 
important role of microglial in neuroprotection against Aβ. 
 
 Though an excess of Aβ can elicit negative effects, it is a natural product of 
metabolism that can be monitored when production and degradation are balanced. In 
fact, studies have shown that low physiological levels of Aβ enhance learning and 
retention. Indeed, Aβ enhances arborization of dendritic-like processes [49], neurite 
growth [50], and cell survival [49]. Nanomolar doses of Aβ were injected into the 
hippocampus of mice that later experienced cognitive dysfunction [51-56]. However, 
when physiological (i.e. picomolar) doses were applied, there was improvement in T-
maze foot shock avoidance task, object recognition, Morris water maze and contextual 
fear memory test for mice [57-60]. Other studies have shown that picomolar doses of Aβ 
increase long-term potentiation. It is, however, still not clear as to what triggers the 
amyloidogenic pathway and distribution of Aβ, but different Aβ forms can localize in 
different areas of the cell (endoplasmic reticulum [ER], mitochondria, endosome, 
nucleus and Golgi) [61-63]. Additionally, clearance of Aβ has been shown to be 
important in homeostasis as mentioned previously via enzymes like NEP, IDE, 
cathepsin, and human presequence protease (hPreP). Notably, all of these are found at 
low level and with lower activity in AD brain and AD transgenic mouse models [64, 65]. 
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Reactive Oxygen Species (ROS) and Aβ 
Mitochondria generate adenosine triphosphate (ATP) by using the electron 
transport chain (ETC), in order to provide energy to drive protons against their 
concentration gradient. The force itself driving the proton into the mitochondria includes 
MMP (charge/electrical gradient), which in turn drives the synthesis of ATP [66]. During 
aging, there is a decrease in mitochondrial activities and an increase in ROS presence 
triggering Aβ synthesis [67-69]. In order for cells to function efficiently, they must have 
healthy mitochondria. Research has shown that increased ROS production is 
associated with mitochondrial damage, which would result in decreased ATP 
production. This can lead to neuronal damage, cognitive deficits, and apoptosis.  
 
There is a strong relationship between Aβ and the mitochondria. In fact Aβ has 
been shown to be associated with and penetrate the mitochondria as intraneuronal 
soluble proteins before depositing as insoluble, extracellular species [70]. Inside the 
mitochondria, Aβ has been shown to inhibit mitochondrial function, increase ROS and 
release cytochrome c [71]. Further studies have shown that ROS increases BACE-1 
activity. Tamagno and colleagues showed that oxidative stress induces BACE-1 
transcription, thereby promoting the production Aβ. In this study, BACE-1 levels were 
increased in response to oxidative stress in normal cells, but not in cells lacking 
presenilins or APP [72]. Clearance and degradation, in addition to production, of Aβ is 
important in homeostasis and studies have also shown that Aβ degradation and 
clearance is down-regulated by ROS [73, 74]. Taken together, it becomes imperative to 
understand further the mechanism by which there is an increase in ROS, and also to 
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extrapolate a means to understand the mechanism by certain antiretrovirals (ARVs) 
may induce Aβ accumulation. 
 
Delving deeper into the mechanism, it has been shown that ROS activates 
pathways leading to BACE-1 expression. Past studies have shown that the 
phosphorylation of eukaryotic initiation factor-2α (eIF2a) occurs via multiple molecular 
mechanisms (e.g. protein kinase RNA-activated [PKR]) and halts general translation of 
proteins, but not BACE-1 translation. This is due to the fact that sustained eIF2α 
phosphorylation paradoxically causes translational activation of a subset of mRNAs, 
including BACE-1 [75, 76]. PKR itself can be activated by viral infection or oxidative 
stress. Therefore EFV could be a strong activator of PKR via ROS production. In 
addition, it would be advantageous for EFV to induce PKR activation because activated 
PKR has a strong antiviral activity on HIV-1 expression and production in cell culture 
and would reduce translation of HIV protein as a protective mechanism. So, this 
overactivation may indeed lead to BACE-1 increase and Aβ deposition, thus playing a 
role in HIV associated neurocognitive disorders (HAND) pathogenesis. 
 
 EFV is a common ARV prescribed worldwide.  Because of its expected long-term 
use in patients it is important to understand the impact it may have on quality of life. 
Based on clinical trials that have indicated symptoms from patients related to the CNS 
and epidemiological studies, which have found Aβ deposits in HIV-infected brains, we 
will explore the correlation between EFV and Aβ accumulation studies [31-40]. We 
hypothesize that EFV will increase Aβ production and decrease Aβ clearance. We 
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developed this hypothesis based on studies that show EFV increases ROS production.  
ROS production promotes both BACE-1 and can decrease microglial Aβ clearance [72, 
77].  
 
Further, mitochondrial function is important to the survival of all cells, and 
especially so in the neuron whose ability to regenerate/differentiate are limited and still 
not completely understood. If EFV, a drug prescribed for a life-time, has negative effects 
on mitochondrial function, it could potentially aid in the development of HAND. We 
hypothesize that EFV will promote ROS production because it has been shown to inhibit 
mitochondrial complex I generating ROS in vitro [78]. This can lead to reductions in 
MMP, and ATP stores. We also expect an increase of BACE-1 enzyme, based on 
Tamagno et al., who showed that oxidative stress promotes BACE-1 activity [72]. 
 
Neurogenesis 
Neurogenesis previously was a term or concept that was mostly accepted or 
understood to cease post-natally. It is now understood that adult neurogenesis exists in 
actuality in the sub-ventricular zone (SVZ) and the sub-granular zone (SGZ) of the 
dentate gyrus (DG) of the hippocampus [79]. The hippocampus plays a key role in 
learning and memory and is extremely susceptible to inflammatory insults that affect the 
brain [79].  Experiments have shown that pro-inflammatory cytokines (like interleukin 6 
for example) reduce neural stem cell (NSC) proliferation [80]. Further, high pro-
inflammatory cytokine and ROS levels have been shown to induce apoptosis and 
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damage developing neurons [81-83]. Thus, these negative changes to the hippocampus 
are associated with neurodegenerative processes seen in AD and HAND. 
 
Neurogenesis incorporates the proliferation and division of NSCs that can give 
rise to new neurons [84]. The exact mechanism by which neurogenesis is hampered 
during HAND is yet to be fully understood. However upon our review, several studies 
have detected correlations of HIV-1 and its effect on neurogenesis [85]. One such study 
showed that neural stem cells could be infected by the HIV-1 virus [86], despite the fact 
that HIV-1 is well known to not infect neurons. In support of this, another study showed 
that pediatric, post-mortem brain tissue had HIV-1 infection of NSCs [87]. In other 
studies, post-mortem brain tissue from HAND patients had fewer adult NSCs in the DG 
than did non-cognitively impaired and non-infected control specimens [88, 89]. This 
study also showed that HIV-1/gp120 reduced the proliferation NSCs in the hippocampus 
[90]. This reduction was correlated to the activation of the p38 mitogen-activated protein 
kinase (MAPK) pathway, which activated arrest of the cell cycle in the G1 phase [88, 
90]. 
 
p38 MAPK, Bax, and ROS 
Eukaryotic cells possess multiple MAPK pathways important for cell regulation. 
They coordinate activation of gene transcription, protein synthesis, cell cycle machinery, 
cell death, and differentiation.  The activation of MAPK pathways can be activated by 
several different stimuli acting through diverse receptor families, including hormones 
and growth factors (i.e. insulin, epidermal growth factor [EGF]), cytokine receptors (e.g., 
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growth hormone), G protein-coupled receptors, seven-transmembrane receptors, 
inflammatory cytokines of the tumor necrosis factor (TNF) family and even 
environmental stresses such as osmotic shock. This activation of MAPK involves a 3-
kinase cascade in which a MAP3K phosphorylates and activates a MAP2K. MAP2K 
then phosphorylates and activates one or more MAPKs [91, 92].  
 
p38 MAPKs have an initial signaling pathway that starts with the activation of 
several MAP3Ks. ROS oxidize thioredoxin (Trx) to dissociate it from apoptosis signal 
regulating kinase 1 (ASK1) for its activation, resulting in the stimulation of the p38 
MAPK pathway [93]. As aforementioned, p38 MAPK is activated by inflammatory 
cytokines and cellular stresses. This activation could play a role in redox signaling. 
ASK1 has been characterized as an ROS responsive kinase and is a MAP3K of the p38 
pathway [94]. ASK1 is activated by various types of stress (ROS, lipopolysaccharide 
[LPS]), but ROS is the most potent [95]. In general, Trx binds to ASK1 inhibiting its 
kinase activity [95]. ROS, however, converts Trx to the oxidized form and dissociates 
Trx from ASK1, inducing ASK1 activity [85, 95]. This relationship was supported when 
ASK1-deficient cells significantly reduced the activation of the p38 MAPK pathways 
even when ROS were increased [96]. This led to the notion that ASK1 is an upstream 
kinase that can be induced by ROS production and activate the downstream p38 MAPK 
pathway. This activation of p38 MAPK can then reduce neurogenesis [88, 90]. 
 
Bcl-2-associated X protein (Bax) is a pro-apoptotic member of the Bcl-2 family. 
The Bcl-2 family of proteins is one of the first groups of proteins to regulate apoptosis. 
	11 
Their classes of proteins either promote cell survival (Bcl-2, Bcl-XL, Bcl-w) or promote 
cell death (Bax, Bak, Bad). Bax is found in many tissues of the body, and promotes 
apoptosis. Its deletion has been shown to induce excess neurons [97, 98]. In fact, Bax-
deficiency was shown to prolong cerebellar neurogenesis and accelerate 
medulloblastoma formation.  Specifically, Bax−/− mice, extended the period of 
neurogenesis into the third week of postnatal life [98]. In opposition, the overexpression 
of Bax promotes cell death and blocks the co-expression of pro-survival proteins [99, 
100]. Bax is predominantly a soluble cytosolic protein, which, upon apoptosis 
translocates to the mitochondrial membranes [101, 102]. This induction of apoptosis 
and translocation to the mitochondria can lead to the loss of MMP and activation of 
caspase-3 [103-105]. Both p38 MAPK and Bax activation have been linked to the 
negative regulation of stem cell proliferation. Studies showed that the inhibition of 
p38MAPK using PD169316 or p38α−/− cells is sufficient to induce a high level of 
neurogenesis spontaneously [106, 107]. 
 
Combination Antiretroviral Therapy (cART) 
HIV treatment had few options prior to 1996. Even though monotherapy was 
available (zidovudine [AZT]), treatment focused primarily on managing opportunistic 
AIDS illnesses and pathogens during that time. Inhibitors were then created to target 
essential proteins/enzymes of HIV [10]. Beginning with monotherapy, antiretroviral 
therapy (ART) has evolved into a combination of several drugs, now termed 
combination antiretroviral therapy (cART). cART drastically improved morbidity and 
mortality rates, suppressing HIV viral load below the levels of detection [108, 109]. With 
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proper adherence to cART, viral replication can be suppressed for decades [10]. While 
cART helps patients live longer and healthier lives compared to pre-cART era, there are 
still factors that limit the extent of treatment and aid in neurodegeneration.  
 
As mentioned, cART is a combination therapy regime with different types of drug 
targets. cART includes protease inhibitors (PIs), nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase 
strand transfer Inhibitors (InSTIs), and fusion inhibitors. These drugs in combination 
prevent and/or delay the progression to AIDS and may decrease the severity of 
neuropathogenesis, but cannot prevent the emergence of milder forms of HAND. Our 
research will focus on NRTIs and NNRTIs, especially the commonly prescribed cART 
regimen for naïve patients Efavirenz (EFV), AZT, and lamivudine (3TC). 
 
Reverse transcriptase is the target for 2 types of drug classes: NRTIs (analogs 
for native nucleoside substrates) and NNRTIs (bind to a non-catalytic allosteric pocket 
on the HIV reverse transcriptase) [10]. The first class of drugs approved by the FDA 
was NRTIs, which were administered as pro-drugs requiring host cell entry and 
phosphorylation by kinases prior to causing an antiviral effects. While there are several 
NRTIs our focus will be AZT and 3TC. AZT was one of the first NRTIs approved for 
ART, and was often used in the first line of defense as approved by World Health 
Organization (WHO) guidelines for adults and children 4 weeks and older. It is also 
used in the prevention of mother to child transmission (MTCT) of HIV [110]. 3TC is also 
used but must be administered in adults and children 3 months of age and older [111]. 
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Further, it should be understood that NRTIs are often used as the backbone of the 
cART regimen [112]. 
 
NNRTIs differ in the site of action on the enzyme and molecular mechanism 
when compared to NRTIs. NNRTI binds and induces the formation of a hydrophobic 
pocket to inhibit reverse transcriptase, changing the conformational shape to reduce 
polymerase activity. EFV, an NNRTI, was first available in 1998 and can be used for 
adults and children 3 months and older weighing at least 3.5 kg [113]. The focus of the 
studies in Chapter 3 and 4 will be EFV. 
 
HIV Associated Neurocognitive Disorders (HAND) 
 Esiri and colleagues observed significant amyloid deposition in the brains of HIV 
infected patients [32]. Other neuropathological studies have shown that HIV infected 
patients have increased Aβ deposition in the brain as well [31-40]. 
 
 These Aβ proteins cause cerebral plaques, a characteristic of the disease. This 
build up is especially prone in the frontal cortex and hippocampus of the brain. Aβ 
causes progressive neuronal loss resulting in the deterioration of the brains high and 
basic functionalities. Along with opportunistic infections commonly seen in HIV patients 
that are common as a result of their decreased immune systems, in recent years 
patients infected with HIV have begun to report mild memory problems as well as 
difficulties in concentration and multitasking even with undetectable viral loads [114, 
115]. Neuropathologically, studies have shown that there is a correlation of HIV infection 
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with increased Aβ deposition to the brain [31-40]  
 
cART and HAND 
While cART has increased long-term survival of the HIV infected population, 
another area of concern has become evident [116]. Over the years, as a result of cART 
availability, there has been a shift from rapid progression to a more subtle 
neurocognitive decline. This neurological diagnosis of HAND encompasses three 
categories based on severity: (1) Asymptomatic Neurocognitive Impairment (ANI), (2) 
Mild/Minor Neurocognitive Impairment (MNI), and (3) HIV Associated Dementia (HAD).  
ANI characterizes the least severe form of HAND, while HAD the most severe form.  
HAND patients are initially assessed based on three main criteria: (1) eliminating co-
morbid conditions or infections that may result in dementia, (2) battery testing 
(evaluated by patients that test below the mean on two cognitive domains), and (3) 
assessing the impairment on performing tasks associated with ADLs [117]. Even though 
ANI patients display no significant inability to perform ADLs, they have deficits in at least 
two of the cognitive areas evaluated by neuropsychological testing.  These tests include 
speed of information processing, sensory-perceptual, motor skills, verbal/language 
skills, and attention/working memory [117]. MND patients experience the criteria for ANI 
in addition to mild interruptions in performing ADLs. HAD, the most severe form of 
HAND, requires a marked cognitive impairment leading to a significant interference with 
performing ADLs; which is in addition to all the requirements for MND [117]. In the pre-
cART era there was an annual incidence of 7% of HAD [118, 119].  Jevtovic and 
colleagues (2009) found that in the post-cART era there was a decrease in HAD 
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diagnosis, while more than 50% of persons living with HIV were diagnosed with some 
form of HAND [120].  
 
HAND in the HIV population can be induced by several factors. One factor may 
be certain components of cART, a combination of several drugs that have drastically 
decreased the morbidity and mortality rates as a result of their ability to efficiently 
suppress the HIV viral load [109]. cART, usually a 3 drug regimen, has contributed to 
the evolution of HIV from a terminal illness to a chronic disease, enabling individuals to 
live closer to the age of AD onset. While cART increases patient lifespan, it may 
contribute to neurocognitive symptomology. In addition, the prospect of ARVs 
contributing to or inducing HAND is not well studied; however, our lab and other 
research groups show that certain ARVs induce oxidative stress and neuronal damage 
in the CNS [121-123]. Data showed negative effects of cART medications on the 
neuronal Aβ production and clearance by microglial phagocytosis. This experiment 
suggested that ART increased Aβ generation in SweAPP N2a cells [124].   
 
Others have conducted clinical studies in this area. For example, studies show 
that significant cognitive symptoms persist in HIV patients despite undetectable plasma 
viral load [114, 115]. Even though some studies show that the most severe cases of 
HAND have decreased, there is still a milder form of HAND requiring evaluation by 
clinicians for patients living with HIV. Furthermore, ARVs have been associated with 
potentially serious side effects. For example EFV (which will be expanded upon further 
in the next paragraph), prescribed worldwide since 1998, has clinical CNS side effects 
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including: cognitive disorders, hallucinations, and insomnia [125-128]. In mice, EFV 
affected anxiety and cognitive performance as well [129]. In addition, long-term use of 
EFV has been shown to correlate with the worsening of neurocognitive functioning 
including speed information processing, verbal fluency, and working memory [125, 130-
133]. Our studies will explore EFV effects on AD-like HAND pathology, and will 
investigate the mechanism by which the effects occur in vitro and in vivo. 
 
EFV, Aβ, and Neurogenesis 
Several studies have explored the toxicity of EFV. Patients taking EFV have also 
been shown to have cognitive disorders even when HIV infection itself is well controlled 
[125]. Robertson and colleagues further showed neurocognitive improvements after 
treatment interruption in stable HIV-patients on EFV compared to patients without EFV 
[132]. The pilot study in our lab showed that some ARVs both alone and in dual 
combination can increase Aβ production and decrease Aβ microglial phagocytosis in 
vitro [124]. In fact, it has been shown that EFV can lead to the inhibition of mitochondrial 
complex I altering NADH/NAD+ balance and the generation of ROS in vitro [78]. 
Moreover, EFV has been shown to cause mitochondrial dysfunction and increases in 
ROS [123, 134, 135]. This mitochondrial dysfunction can directly affect p38 and BACE-
1, which is significantly activated by ROS [72, 88, 90]. This could suggest the role Bax 
activation has on MMP, which was shown to be decreased by EFV [123].  
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Objectives and Hypothesis 
Having compiled all data, our main objective was to determine if EFV has a 
significant effect on Aβ production and neurogenesis, and to identify the underlying 
mechanism of action, which may enable us to develop a novel therapeutic approach. 
We hypothesized that exposure to EFV will increase Aβ accumulation and decrease 
neurogenesis leading to a process that could contribute to HAND.  
 
Chapter 3: Determined the effect of EFV on Aβ production and clearance and 
explored the mechanism by which it occurs. We measured changes in (1) Aβ 
production, (2) Aβ clearance, (3) oxidative stress markers (ROS, MMP, and ATP 
levels), and (4) BACE-1 expression. 
   
Chapter 4: Determined the effect of EFV on neurogenesis. We measured (1) 
oxidative stress markers (MMP, ATP), (2) proliferation markers (MTT, BrdU, Dcx), 
and (3) protein expression (p38 MAPK, Bax, Caspase-3). 
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Fig. 1.1 Hypothesis Overview  
We hypothesize that the EFV will increase oxidative stress as several studies have 
already shown that it inhibits mitochondrial function. This should result in the overall 
accumulation of Aβ via BACE-1 activation and decrease neurogenesis via p38 
MAPK/Bax activation. 
  
EFV	
éROS/êMMP	
éBACE1	
éBeta	Amyloid	Accumulation	
ép38	MAPK/éBAX	
êNeurogenesis	
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CHAPTER TWO 
MATERIALS AND METHODS2 
 
Cell Culture  
SweAPP N2a Cells 
Murine N2a cells were transfected with the Swedish mutant form of APP 
(SweAPP). N2a cells were cultured in complete DMEM supplemented with 10% fetal 
calf serum, and penicillin and streptomycin 100U/ml (Life Technologies, Carlsbad, CA, 
USA). Cultured media was exchanged approximately every 3-5 days.  Treatments were 
performed in the same media used in the cell culture. 
 
Rat Neural Stem Cells 
Rat NSCs (EMD Millipore, Billerica, MA USA, cat# SCR021) were cultured in 
DMEM/F12 media supplemented with serum free Neuro 27 medium (EMD Millipore), 
human fibroblast growth factor 2 (FGF-2, EMD Millipore), 20 ng/ml, human endothelium 
growth factor (hEGF, Peprotech, Rocky Hill, NJ, USA), and 20 ng/ml, L-glutamine 2mM 
(Life Technologies), as well as penicillin and streptomycin 100U/ml (Life Technologies). 
Culture media were exchanged every 2 days. 10-cm dishes and 96-well plates were 
pre-coated with 10 µg/ml of poly-L-ornithine (EMD Millipore), followed by laminin (EMD 																																																								2	Portions of this chapter have been previously published (Brown LAM, et al., 2014; Jin, J, et al, 2016) and are 
utilized with permission of the publisher. 	
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Millipore) at a concentration of 10 µg/ml in PBS solution. NSC treatments were 
performed during passages 2-6. Treatments were performed in the same medium used 
for cell culture. 
 
Mouse Experiments 
Tg2576 
It is necessary to use an amyloid-depositing mouse model because wild type 
mice are incapable of forming appreciable mature amyloid plaque during the course of 
normal aging [1]. For that reason throughout these experiments, cells and mouse 
models with the Swedish APP gene construct will be used. The purpose for using such 
a system is to be able to not only have ease in quantifying Aβ production but to also 
analyze BACE-1 expression and activation. The Swedish APP gene is a double 
mutation (K670N and M671L) and increases Aβ 6-8 fold. The mouse model used, 
Tg2756, expresses APP695 with the Swedish double mutation, controlled by the 
hamster PrP promoter. These mice show Aβ deposition around 9 months  [2]. 
 
Female Tg2576 mice were purchased at 8 months of age and treated with EFV, 
AZT, 3TC, and combination in chow for 10 days. The 8-month time point was chosen 
because it is 1-3 months earlier than the expected Aβ deposition in this model [2]. This 
will serve as support that ARVs cause early onset of Aβ pathology. 
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C57BL/6J 
C57BL/6J female mice at the age of eight months old were purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA), and were housed in environmentally 
controlled conditions (12:12 hour light : dark cycle at 21±1 °C) and provided food and 
water ad libitum. 
 
Housing and Maintenance 
All animal work was approved by the University of South Florida Institutional 
Animal Care and Use Committee (IACUC). They were housed in the Byrd Alzheimer’s 
Institute under a 12 hour light-dark cycle. Food and water were provided ad libitum.  
 
Doses and Concentrations 
Tg2576 mice: The dose used in our study for each drug is based on several 
factors: (1) human clinical therapy [3], (2) body weight, (3) short dosing period of only 10 
ten days, (4) administration method being in chow, and (5) doses used in previous 
publications [4-7]. The mice were evaluated for changes in cerebral Aβ after 10 days of 
treatment with each ARV (singly or combined) or with vehicle control. Our experimental 
groups included oral treatments of: Vehicle (chow no additives), AZT 50 mg/kg, 3TC 40 
mg/kg, EFV 15 mg/kg, and combination of drugs (AZT/3TC/EFV). 
 
C57BL/6J Mice: The dose of EFV administered in vivo (20 mg/kg) was based on 
the body weight of the mice, the dosing period of 30 days as well as our [8] and other [9] 
previous publications. 
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Tissue Isolation and Preparation 
Administration of EFV and tissue processing of 8-month-old C57BL/6J mice was 
randomly divided into two groups matched by body weight and gender. One group 
received EFV via intraperitoneal (i.p.) injection at a dose of 20 mg/kg daily (8 mice) in 
vehicle control (5% DMSO, 17% Tween 80 in 5% glucose solution) [10] while the other 
group received vehicle control only via i.p. injection (7 mice). The dose used in the 
present study (20mg/kg) is in the range used in other studies (10-30 mg/kg) 
investigating various effects of EFV in rodents [9, 11-13]. The injection period was 4 
weeks. On the final week, mice received 50 mg/kg of BrdU (Sigma-Aldrich, St Louis, 
MO, USA) in phosphate buffered saline (PBS) via i.p. injection daily for 5 consecutive 
days. 24 hours later, all mice were deeply anesthetized with 1-2 % isoflurane, and 
transcardially perfused with 20 ml of cold PBS followed by 20 ml of 4% 
paraformaldehyde (PFA) in PBS. Mouse brain tissues were removed, post-fixed into 4% 
PFA (pH 7.4) at 4°C overnight, and then neutralized with 30% sucrose in PBS (pH 7.2). 
Mouse brains were sectioned using a microtome (Leica, Germany) with 40 µm 
thickness. Sagittal sections from the right hemisphere were used for 
immunohistochemistry staining. 
 
Protein Analysis 
Immunocytochemistry 
NSCs were grown in 4-well chambered coverglass (Lab-Tek) at density of 3×104 
for 24 hours. After exposure to 5 µM of EFV for 24 hours, 10 µM of BrdU (Sigma-
Aldrich) was added at 37°C for 2 hours. Next, 4% formaldehyde in PBS was added to 
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each well at room temperature for 20 minutes for fixation. NSCs were blocked with 3% 
donkey serum, incubated with mouse anti-nestin antibody (1:500; Covance, Dedham, 
MA, USA) at 4°C overnight, and then incubated with secondary Alexa Fluor 594 Donkey 
anti-mouse IgG at room temperature for 1 hour. NSCs were treated with 2N HCl for 10 
minutes at room temperature to denature DNA and were neutralized by citric acid buffer 
(pH 7.4) for 10 minutes. Cells were blocked with 3% donkey serum incubated with rat 
anti-BrdU antibody (1:250; Accurate Chemical & Scientific, Westbury, NY, USA) at 4°C 
overnight, and then incubated with secondary antibody Alexa Fluor 488 Donkey anti-Rat 
IgG at room temperature for 1 hour. Images were taken using an inverted microscope 
IX53 and a DP22 color camera (Olympus, Center Valley, PA, USA). The proliferation of 
NSCs was measured by the percentage of double fluorescence staining of BrdU (green) 
and nestin (red) over total nestin positive cells. 
 
Immunohistochemistry 
Sections were blocked with 5% goat serum, 2% BSA in PBS, and 0.1% Triton X-
100 followed by hybridization at 4°C overnight with goat anti-doublecortin antibody (Dcx, 
1:200; Santa Cruz, Dallas, TX, USA). Sections were then washed, and incubated with 
the biotinylated anti-Goat IgG (1:200, Vector Laboratories, Burlingame, CA, USA). For 
BrdU analysis we followed a previous protocol [14]. Briefly, sagittal sections were 
treated with 50% formamide / 2 × SSC (0.3 M NaCl, 0.03 M sodium citrate) at 65°C for 
2 hours, rinsed in 2 × SSC, incubated in 2N HCl for 30 min at 37°C, rinsed with borate 
buffer (pH 8.5) for 10 minutes, and then washed with PBS twice. Sections were 
incubated with rat anti-BrdU antibody (1:250; Accurate Chemical & Scientific) at 4°C 
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overnight, and with biotinylated goat anti-rat IgG (1:200), and developed in DAB 
solution. After mounting the sections onto slides, quantification of positive Dcx and BrdU 
immunostaining in the subventricular zone (SVZ) was conducted by scanning the slides 
using an Axioscan Z.1 scanner (Zeiss, NY, USA) to produce 20x digital images. Using 
the NearCYTE STI computer program (nearcyte.org), a researcher blind to the 
treatment conditions outlined the region of interest that was then compared to a user-
defined pixel color threshold. This file was applied to all of the sections to be analyzed in 
order to designate positive staining within the determined area. The files were batch 
processed to generate a ratio of positive stain to total area of for each contour drawn on 
a slide image. Regarding active caspase-3 analysis, tissue sections were 
immunostained by free floating method. The primary antibody used was rabbit anti-
active caspase-3 antibody (1:250). Vectastain ABC and nickel DAB reagents (Sigma-
Aldrich) were used to identify active caspase-3 positive cells. Sections were mounted 
and imaged manually using an Olympus BX51 microscope with U-CMAD3 camera. The 
Images were taken by Dp 70 software and analyzed by ImageJ 1.47v. The entire area 
of the SVZ (50 fields, 0.15 mm2 each,) was analyzed from three sagittal brain sections 
per mouse. Each was separated by a 240 µm interval. The number of positive active 
caspase-3 positive cells per mm2 was quantified. 
 
Western Blot  
Tg2576 Mice/SweAPP N2a Cells: For the in vivo studies of Aβ associated 
pathology, left hemispheres of 8 month old transgenic and wild-type mouse brains were 
lysed in ice-cold lysis buffer and aliquots were electrophoretically separated using 
	40 
16.5% Tris–tricine gels.  Protein expression for selected proteins (including beta 
amyloid, BACE-1, Bax, etc) were analyzed using Western blot. After washing tissues or 
cells with PBS, they were homogenized using 1X lysis buffer, 0.1% protease inhibitor 
phenylmethylsulphonyl fluoride (PMSF), and protein inhibitor cocktail, and stored at -
80˚C.  Total protein content was estimated using the Bio-Rad protein assay in strict 
accordance with manufacturer's directions. Equal amounts of protein were loaded per 
sample for separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). SDS-PAGE was performed using gels ranging from 8%-16.5% Tris–
tricine gels. Electrophoresed proteins were transferred to PVDF membranes (Bio-Rad). 
Membranes were blocked in Tris-buffered saline (TBS) containing 5% (w/v) non-fat dry 
milk. Membranes were incubated in primary antibodies were overnight at 4o C. After 
membranes were washed 3 times for 10 minutes with PBS-T.  Appropriate HRP-
conjugated IgG secondary antibody as a tracer (i.e. anti-mouse, anti-rabbit) for 1 hour at 
room temperature was then used. Blots were reprobed with a reference anti-actin 
antibody, which allows for quantification of total protein. For both in vitro and in 
vivo studies, blots were developed and then assessed densitometrically using using the 
Fluor-S MultiImager with Quantity One software from Bio-Rad (Hercules, CA, USA). 
Immun-Blot polyvinylidene difluoride (PVDF) membranes were purchased from Bio-
Rad. Tris-buffered saline was obtained from Bio-Rad and luminol reagent was obtained 
from Pierce Biotechnology  (Rockford, IL, USA).	
 
NSCs: Following 5 µM EFV or vehicle control treatment, NSCs were harvested 
and lysed by RIPA buffer in 1 mM PMSF, protease inhibitor cocktail, and phosphatase 
	41 
inhibitor cocktail (Sigma-Aldrich). Protein concentrations were detected with a BCA 
assay kit. 30 to 50µg of total proteins were applied to SDS-PAGE (10% polyacrylamide 
gel) and transferred to PVDF membranes (GE Healthcare Biosciences, Marlborough, 
MA, USA). Blots were incubated for 1 hour in 0.1% Tween 20 in TBS containing 5% 
nonfat dry milk. After 3 washes with PBS in 0.1% Tween 20, membranes were 
incubated for 16 hours with one of the following primary antibodies: phospho-p38 
mitogen activated protein kinase (MAPK) antibody (Thr180/Tyr182; Cell Signaling 
Tech., Danvers, MA, USA), total p38 MAPK antibody (Cell Signaling Tech), or Bax 
polyclonal antibody (EMD Millipore) at 4°C for 1 hour with horseradish peroxidase-
conjugated secondary antibodies (diluted 2000-fold) at room temperature. Target 
proteins were visualized using SuperSignal West Pico chemiluminescent substrate 
(Thermo Scientific, Rockford, IL, USA). Blots were stripped and re-probed with anti-β-
tubulin III (1:8000, Covance). The resulting protein bands were scanned using an hp 
Laser Jet 9050 mfp System (hp Inc., Palo Alto, CA, USA), and densitometric analysis of 
each protein band was performed using ImageJ v1.45 (NIH, Bethesda, MD, USA). To 
normalize for protein loading, the densitometric analysis of each band was divided by 
the β–tubulin III band from the same membrane for Bax and total p38MAPK for 
phospho-p38MAPK. 
 
Aβ ELISA 
An ELISA is used to measure the concentration of an analyte in solution. In 
general, an ELISA occurs in 4 steps coating, blocking, detection and analysis. In this kit, 
coating adds an antibody specific for NH2 terminus of Aβ. Standards of known Aβ 
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content, controls, and unknown samples are then pipetted into the wells and co-
incubated with antibody specific for the COOH-terminus of the Aβ sequence. The bound 
COOH-terminus antibody was detected by the addition of a horseradish peroxidase. 
After removal of all the unbound enzymes, a substrate solution was added, which works 
on the enzyme to produce color. Cells were then be plated and stimulated for 18 hours 
with EFV, AZT, and 3TC both alone (10 µM) and in combination (10 µM). Cell-free 
supernatants were collected and Aβ1-40, 42 peptides were detected directly from the 
conditioned media and quantified in these samples using Aβ1-40, 42 ELISA kits (Life 
Technologies) in accordance with the manufacturer's instructions. 
 
Assays 
MMP 
The 5,5',6,6'-tetrachloro-1,1'',3,3''-tetraethylbenzimidazolylcarbo-cyanine iodide 
(JC-1) mitochondrial membrane potential (MMP) Detection Kit (Biotium: Fremont, CA, 
USA) uses a unique cationic dye to measure MMP changes in cells. The lipophilic dye 
enters the negatively charged mitochondria to accumulate. When the critical 
concentration is exceeded, the dye aggregates. However it can also localize in the 
cytosol in a monomeric form. Therefore, healthy cells can be stained both red and 
green. In apoptotic cells the MMP collapses and JC-1 is unable to accumulate in the 
mitochondria and remains in the cytoplasm in the monomeric form. Healthy cells are 
therefore distinguishable by the fact that it has both red and green staining. JC-1 
aggregates in the mitochondrial membranes in non-apoptotic cells are detectable as a 
red fluorescence at 590 nm, while it exists in the green fluorescent monomeric form at 
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530 nm of apoptotic or necrotic cells. 
 
SweAPP N2a: In short, cells were treated for 18 hours with ARVs EFV, AZT, or 
3TC alone and in combination. Cell media was removed and replaced with 1X JC-1 for 
15 minutes. MMP analysis was performed using a JC-1 (ex: 530/25, em: 590/35) MMP 
detection kit. The value of red fluorescence divided green fluorescence represented 
MMP. 
 
NSCs:  In brief, NSCs were plated in 96-well plates at a density of 104 cells/well 
for 24 hours. EFV was applied at concentrations of 0.5 µM, 1 µM, 2 µM, 5 µM, and 10 
µM. Vehicle control (negative control) and H2O2 (100 µM, positive control) were also 
examined. After 6 hr treatment, JC-1 was added into culture media for 15 minutes at 
37°C. JC-1 either accumulated on mitochondrial membranes (non-apoptotic cells, red) 
or remained in the cytoplasm (apoptotic cells, green) [15]. Media was exchanged for 
PBS. 
 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFA) 
Cellular ROS generation was analyzed using H2DCFDA (ex: 485/20, em: 528/20) 
from the ROS detection kit (Invitrogen: Carlsbad, CA, USA). H2DCFDA is permeable to 
cell membranes and oxidized to a fluorescent form by ROS including hydrogen peroxide, 
hydroxyl radicals and peroxynitrite. In short, cells were plated in a black 96-well plate 
and the drugs were administered (10µM). The treatment was discarded at 30 and 60 
minutes and H2DCFDA was added and incubated for 30 min. H2DCFDA was then 
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removed and ROS production was measured at different time points indicated. 
 
ATP 
ATP determination was performed using the ATP determination kit (Invitrogen). 
ATP determination kit is based on the requirement of luciferase for ATP to produce light. 
In short, reaction buffer containing 1 mM dithiothreitol, 0.5 mM luciferin, and 12.5 
µg/ml luciferase was added to treated cells. Unknowns were extrapolated from a 
generated ATP standard curve. After treatment, cells were lysed by Tris lysis buffer on 
ice for 30 minutes, and subjected to sonication for 30 seconds at 40% power. Next, 90 
µl of the premixed solution, including d-luciferin, firefly luciferase, dithiothreitol, 
adenosine 5′- triphosphate, and assay buffer was transferred into 96-well plates 
(Greiner Bio-One, Monroe, NC, USA). Following, 10 µl of cell lysate solution or ATP 
standard solutions were added into the wells with triplication. Relative luminescence 
units (RLU) were detected with a microplate reader (Synergy H1, Biotek, Winooski, VT, 
USA). Percentages of EFV treatment over vehicle control represented intracellular ATP 
levels. 
 
SweAPP N2a: Cells were plated and incubated at 37°C for 24 hours. Cells were 
then treated with cART drugs (AZT, 3TC, EFV, and in combination) at 10 µM for 48 
hours. 
 
NSCs: Briefly, NSCs were plated in 12-well plates at a density of 3×105 per well 
and incubated at 37°C for 24 hours. Then the cells were treated with a series of 
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concentrations of EFV (0.5 µM, 1 µM, 2 µM, 5 µM, and 10 µM), vehicle control, and 
positive control (H2O2, 100µM) for 24 hours. 
 
LDH 
Cell death in vitro was measured by lactate dehydrogenase (LDH) assay kit 
(Thermo Scientific). NSCs were plated in 96-well plates at a density of 104 per well for 
24 hours and then treated with EFV (0.5 µM, 1 µM, 2 µM, 5 µM, and 10 µM), vehicle 
control, and cell lysis buffer (positive control, 30 minutes) for 24 hours. 50µL of cell 
culture media from each treatment were transferred to a flat bottom 96-well plate, and 
50µL of reaction mixture (supplied in kit) were added into each well and incubated at 
room temperature for 30 minutes. After adding stop solution, OD at 490 nm subtracted 
from the OD at 680 nm represented the LDH value. 
 
MTT 
Cellular viability was measured by the Cell Proliferation Kit/MTT assay (Roche, 
Indianapolis, IN, USA). NADPH-dependent enzymes reduce MTT tetrazolium dye (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to its insoluble formazan 
crystals in living cells. These purple in color crystals can then be solubilized and 
measured at 570 nm for absorbance levels, with high absorbance levels indicating a 
higher number of cells.  
 
Briefly, NSCs were plated on pre-coated 96-well plates at a density 104 cells per 
well and incubated at 37°C in 5% carbon dioxide for 24 hours. After treatment with a 
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series of concentrations of EFV, vehicle control (ctrl; <0.1% DMSO in PBS), or H2O2 
(100 uM; positive control) for 24 hours, 10 uL of MTT solution (5 mg/ml) was added into 
each well and incubated at 37o C for 4 hours. Next, 100 uL of solubilization (10% SDS 
in 0.01 M HCL (was added to each ell and incubated at 37o C overnight. Optical Density 
(OD) was detected at a wavelength of 550 nm via microplate reader (Synergy H1, 
BioTek). The percentage of treatment OD divided by the vehicle control OD represented 
the NSC proliferation value. 
 
Other Protocols 
Microglial Phagocytosis 
Primary mouse microglia were treated with “aged” Aβ1-42 peptide conjugated with 
FITC (from BioSource Life Technologies: dissolved in dH20 and pre-incubated for 24 h 
at 37°C to assist aggregation and form fibrils) with ARVs (AZT, 3TC, EFV) both alone 
(10 µM) and in combination (10 µM). The total cellular protein of all groups was 
quantified and adjusted using the Bio-Rad BCA protein assay. Extracellular and cell 
associated FITC-tagged Aβ was quantified using a SPECTRAmax GEMINI microplate 
fluorometer (Molecular Devices Corp.: Sunnyvale, CA, USA) with an Ex/Em= 538/485 
nm. Microglial cells were rinsed 3 times in Aβ-free complete medium, and the media 
was exchanged with fresh Aβ-free complete medium for 10 minutes both to allow for 
removal of non-incorporated Aβ and to promote concentration of the Aβ into 
phagosomes. The relative mean fluorescence values for each sample at 37°C and 4°C 
at the indicated time points were determined and calculated as: (mean fluorescence 
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value for each sample at 37°C - mean fluorescence value for each sample at 4°C) to 
quantify both extracellular and cell associated FITC-labeled Aβ. 
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Table 2.1: Antibody Chart 
Antibody Concentration 2o Antibody Company Method 
Nestin 1:500 Alexa Fluor 594 anti mouse IgG Covance ICC 
BrdU 1:200 Alexa Fluor 488 anti-rat IgG 
Accurate 
Chemical & 
Scientific 
ICC 
Doublecortin 1:200 Goat Santa Cruz IHC 
BrdU 1:250 Rat 
Accurate 
Chemical & 
Scientific 
IHC 
Caspase-3 1:250 Rabbit Sigma-Aldrich IHC 
6E10 1:1000 Mouse Covance WB 
BACE-1 1:1000 Mouse Sigma-Aldrich WB 
Phospho-p38 
MAPK 1:1000 Rabbit Cell Signaling WB 
Total p38 MAPK 1:1000 Rabbit Cell Signaling WB 
Bax 1:1000 Rabbit EMD Millipore WB 
Beta Actin 1:1500 Mouse Sigma-Aldrich WB 
Beta Tubulin III 1:8000 Mouse Covance WB 
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CHAPTER THREE 
EFAVIRENZ PROMOTES Aβ ACCUMULATION3 
 
Introduction 
There has been considerable growth in patient's receiving combination 
antiretroviral therapy (cART) in recent years [1]. Up to approximately 50% of long-term 
HIV-infected patients experience HIV associated neurocognitive disorders (HAND) [2]. 
Most recently it was shown the non-nucleoside reverse transcriptase Inhibitor (NNRTI) 
efavirenz (EFV) is associated with cognitive disorders even in asymptomatic HIV-
infected patients [3]. A randomized controlled study [4] found subjects receiving EFV-
containing regimens showed less improvement from baseline on instruments examining 
speed of information processing and executive function than patients not on EFV. EFV 
has substantial rates of central nervous system (CNS) side effects aside of cognitive 
impairment including sleep and dreaming disturbances and anxiety [5-7] that can 
interfere with adherence and tolerability as well [8]. 
 
Amyloid-beta (Aβ) peptide generation and aggregation as plaques are 
traditionally known as key events in the development of Alzheimer's Disease (AD; [9-																																																								3	Portions of this chapter have been previously published (Brown LAM, et al., 2014) and are utilized with permission 
of the publisher. 	
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12]). The peptides have been evidenced to be neurotoxic, as they are reported 
mediators of inflammation [13, 14], and oxidative stress [15]. Aβ peptides are 
produced via the amyloidogenic pathway of amyloid precursor protein (APP) 
proteolysis, which involves the actions of β and γ-secretases [12, 16]. Initially, β-
secretase (BACE-1) cleaves APP, creating an Aβ-containing carboxyl-terminal fragment 
known as β-C-terminal fragment (β-CTF) [17]. This proteolysis also generates an 
amino-terminal, soluble APP-β (sAPP-β) fragment, which is released extracellularly. 
Intracellularly, β-CTF is then cleaved by a multi-protein γ-secretase complex that results 
in generation of the Aβ peptide and a smaller γ-CTF [18]. In the human brain Aβ1-40 is 
the predominant form whereas Aβ1-42 represents about 10% of brain Aβ and has a 
greater propensity to form neurotoxic oligomeric and aggregated species [19-21]. 
 
The rapid, early clinical phase-in of cART required dose de-escalations 
secondary to toxicities suggested to be related to mitochondrial drug side effects [22]. 
Mitochondrial dysfunction can result in an elevation of reactive oxygen species (ROS) 
that in turn promote amyloidogenic APP processing by inducing BACE-1 activity [23]. 
Such mitochondrial stress has also been reported occurs in patients taking lamivudine 
(3TC), zidovudine (AZT) and especially EFV [24-26]; a commonly used cART 
regimen [27-29]. In light of the increasing life-span's imparted by cART, the 
mitochondrial dysfunction promoted by cART [24, 25, 30-32], and the age associated 
risk for developing amyloid pathology [33], it is not surprising that a body of 
epidemiological data suggests significant numbers of long-term HIV survivors are at 
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elevated risk of developing early brain aging in the form of AD like pathology including 
Aβ deposition [34-40].  
 
As a result, we hypothesized that Aβ pathology may be produced via the 
amyloidogenic pathway of APP proteolysis, which involves the actions of BACE-1 [12] 
and sought to test this with in vitro and in vivo models. Our results indicate that EFV is 
the primary antiretroviral in this commonly used EFV containing regimen: 
EFV/3TC/AZT, which is responsible for its promotion of Aβ pathology [27-29]. 
 
Results 
Epidemiological reports indicate that HAND persists in patients even with good 
viremic control who take EFV [3]. Previous studies have shown that cART imparts 
mitochondrial toxicity in the form of elevated ROS [24, 25]. A high ROS 
microenvironment has been shown to promote the activity of BACE-1, a key enzyme the 
generation of Aβ in the brain [23]. Brain oligomeric [41] and Aβ1-40,42 [42] have been 
correlated with cognitive impairment. Since the EFV containing regimen may promote 
mitochondrial dysfunction [24, 25, 32, 43] which could result in increased BACE-1 
activity, we investigated the effect of a commonly used EFV containing cART regimen 
[27-29] for its ability to upregulate Aβ production via activation of BACE-1 and 
amyloidogenic APP processing and also for its ability to reduce microglial phagocytosis 
of Aβ. 
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BACE-1 is involved in Aβ generation promoted by the EFV containing cART regimen in 
cultured SweAPP N2a cells 
Using similar conditions as in our prior investigations [44], SweAPP N2a cells 
were treated with the EFV containing regimen: 3TC, AZT, EFV or each drug singly at 10 
µM in addition to PBS control for 18 hours. Aβ40 and Aβ42 peptides were then measured 
in conditioned media from these cells by ELISA and Western blot (Fig. 3.1A–C) while 
BACE-1 expression was measured in cell lysates by Western blot analysis (Fig. 3.1D–
E). The EFV containing regimen increased Aβ40 and Aβ42 production in SweAPP N2a 
cells significantly (p < 0.05). Importantly, we found that EFV alone was more potent than 
the EFV containing regimen in terms of significantly increasing Aβ40 and Aβ42 production 
by these cells (p < 0.001). Additionally EFV or the EFV containing regimen increased 
BACE-1 expression in SweAPP N2a cells significantly (p < 0.001). These data would 
suggest that 3TC and/or AZT somehow reduce the toxicity of EFV in terms of promoting 
amyloidogenic APP processing and that EFV is the primary agent promoting Aβ 
production in SweAPP N2a cells. There is some evidence to indicate that AZT may 
indeed have a neuroprotective effect [45, 46], which could explain why the EFV 
containing regimen is less potent in its amyloid producing effects compared to EFV 
alone. 
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Figure 3.1: EFV or EFV/3TC/AZT treatment promotes Aβ generation in cultured 
neuronal cells via BACE-1 activation in vitro.  
Aβ species were analyzed in cell lysates from SweAPP N2a cells (A) by ELISA. Data 
are represented as the mean ± of a percentage of Aβ peptides secreted 24 h after 3TC, 
AZT, EFV, or 3TC/EFV/AZT administration, relative fold over control. Significant 
increases in Aβ were observed in EFV or EFV/3TC/AZT treated cells compared to 
control (***p < 0.001 and **p < 0.05 respectively by ANOVA). (B) Western blot (6E10 
antibody) of conditioned media shows increased oligomeric Aβ species vs. s-APP-α 
(control) in the EFV or EFV/3TC/AZT treated cells (***p < 0.001 and **p < 
0.05 respectively). (D) BACE-1 expression in cultured media revealed significant 
differences between EFV or EFV/3TC/AZT treated cells compared to untreated control 
(***p < 0.001). β-actin is used for the internal loading control. Results are representative 
of three independent experiments. 
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Cerebral amyloidosis in Tg2576 mice is increased by EFV or the EFV containing cART 
regimen 
Brain Aβ deposition is a pathognomonic feature of AD [47], and oligomeric Aβ 
species are thought to be a driving force in AD-type neurodegeneration [48-51]. They 
may also play a role in HAND development [35-40]. The transgenic Tg2576 
mouse [52] is a widely used model of cerebral amyloidosis, and we purchased them 
from Taconic (Germantown, NY, USA) at 8 months of age. They were evaluated for 
changes in cerebral Aβ after 10 days treatment with each antiretroviral singly or 
combined as well as vehicle control. Western blot analysis of brain homogenates 
revealed significantly increased Aβ species in both the EFV and EFV containing 
regimen groups (p < 0.01); again suggesting that EFV accelerates cerebral amyloidosis 
as opposed to having a cumulative effect with 3TC and AZT. Indeed AZT is most likely 
behind the reduced potency of the EFV containing regimen compared to EFV alone in 
terms of Aβ pathology in light of reports that it may be neuroprotective [45, 46, 53]. 
Additionally EFV or the EFV containing regimen increased BACE-1 expression 
significantly (p < 0.001) (Fig 3.2). 
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Figure 3.2: EFV/3TC/AZT increases soluble Aβ levels in Tg2576 mice via BACE-1 
activation in vivo. (A) Aβ40, 42 peptides were analyzed in brain homogenates from 8 
month old Tg2576 mice by ELISA (n = 5 mice for each group). One-way ANOVA 
followed by post hoc comparison revealed significant differences between control 
(Tg2576 mice treated with PBS) and EFV or EFV/3TC/AZT -treated Tg2576 mice (***p 
< 0.001 and **p < 0.05 respectively with n = 5 mice/group). (B) Western blot of brain 
homogenates using anti-Aβ1-17 antibody (6E10) shows total APP and bands 
corresponding to soluble Aβ oligomer species. β-actin was an internal control. A t-
test revealed significant differences in soluble Aβ species between EFV and 
3TC/AZT/EFV-treated compared to, 3TC or AZT treated Tg2576 mice (**p < 0.01) (D) 
BACE-1 expression in brain homogenate of Tg2576 mice significantly was increased in 
EFV or EFV/3TC/AZT -treated Tg2576 mice (***p < 0.001). 
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EFV promotes mitochondrial stress in SweAPP N2a cells  
To determine if EFV or the EFV containing cART regimen could promote 
mitochondrial stress in an amyloid producing model, SweAPP N2a cells were treated 
with EFV, 3TC, AZT, or all three antiretrovirals combined in addition to vehicle control 
for 48 hours. We performed three separate assays to determine general mitochondrial 
function. These included analyses of cellular ATP production, mitochondrial membrane 
potential (MMP), and ROS production. EFV or the EFV containing regimen were most 
potent in reducing mitochondrial function. Mitochondria produce approximately 90% of 
the total cellular ATP in neurons [54]. We therefore first examined ATP levels in 
SweAPP N2a cells as a measure of mitochondrial function. Cells treated with EFV or 
the EFV-containing regimen had greatly decreased ATP levels (p < 0.001) although the 
EFV containing regimen had slightly less ATP depletion than EFV alone. Mitochondria 
from SweAPP N2a cells treated with EFV or the EFV containing regimen showed 
significantly reduced MMP compared to 3TC or AZT treated SweAPP N2a cells; 
mirroring the results with the ATP analysis. The MMP is an indicator of electron 
transport chain function (Fig. 3.3) [54]. 
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Figure 3.3: cART treatment of SweAPP N2a cells promotes mitochondrial 
dysfunction.  
(A) ATP levels are reduced in EFV or EFV/3TC/AZT treated SweAPP N2a neuron 
cells: SweAPP N2a cells were grown with 10 µM of each medication or all three 
medications combined for 48 h. We found a significant decrease in ATP levels in cells 
treated with EFV or 3TC/AZT/EFV (***p < 0.001). (B) MMP is reduced in EFV or 
EFV/3TC/AZT SweAPP N2a cells: In accord with reduced ATP levels we found a similar 
reduction in MMP in the EFV or EFV/3TC/AZT treated groups (***p < 0.001)  
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 Mitochondria are the main source of cellular ROS production in the brain, thus 
the rate of ROS reflects the efficiency of mitochondrial function as well [54] (Fig. 3.4). 
EFV or the EFV containing regimen caused a large increase in ROS production. AZT 
and 3TC did not cause a significant rise thus explaining the reduced potency in terms of 
promoting ROS production of the three drug combination versus EFV alone. From the 
three cell-based assays that were utilized to monitor different parameters of 
mitochondrial function, EFV was identified as the most deleterious compound in our 
screen of this commonly used cART regimen [27-29]. From all three assays we see that 
AZT and 3TC reduce this effect promoted by EFV. 	
Microglial phagocytosis of Aβ1-42 peptides is opposed by EFV 
Amyloid load in the brain is affected not only by production, but also by its 
clearance from the brain via microglia mediated mechanisms [55]. To determine 
whether the EFV containing regimen could affect microglial clearance of Aβ and further 
promote amyloidosis, we performed a phagocytosis assay with primary mouse microglia 
in the presence of EFV, 3TC, AZT or all three antiretrovirals combined in addition to 
vehicle control. Following detection of FITC-tagged Aβ1-42 in extracellular and cell 
associated fractions, we again found that EFV or the EFV containing regimen inhibited 
microglial phagocytosis/clearance. These two treatments significantly inhibited 
microglial phagocytosis of Aβ1-42 peptides as determined by high levels of peptide 
remaining in the cultured media (extracellular) (p < 0.001 and p < 0.05 respectively). In 
addition, EFV or the EFV containing regimen tested also significantly reduced levels of 
phagosomal (cell associated) Aβ1-42 (p < 0.001 and p < 0.05 respectively). Also, when 
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comparing cell associated Aβ1-42 levels of  EFV compared to the three drug combination 
and to the levels of these compounds alone, the differences suggest the major 
reduction in phagocytosis is imparted by EFV and the addition of the other two 
antiretrovirals of the regimen are not additive in nature. Importantly, when comparing 
the levels of extracellular Aβ1-42 to that of cell associated we can see that the 
phagocytosis/clearance profiles are relatively congruent for each treatment condition. 
That is to say, when a given treatment maintains high levels of extracellular Aβ1-42, the 
corresponding cell associated levels are relatively low. Not only does this apparent 
relationship between extracellular and cell associated Aβ1-42 levels confirm the accuracy 
of the assay, but also furthers the overall significance of the inhibition of microglial 
phagocytosis by the antiretrovirals  (Fig 3.5) [44]. 	
Statistical Analysis 
All data were normally distributed; therefore, in instances of single mean 
comparisons, Levene's test for equality of variances followed by t-test for independent 
samples was used to assess significance. In instances of multiple mean comparisons, 
analysis of variance (ANOVA) was used, followed by post-hoc comparison using 
Bonferonni's method/correction. Alpha levels were set at 0.05 for all analyses. The 
statistical package for the social sciences release 10.0.5 (SPSS Inc., Chicago, IL, USA) 
was used for all data analysis. 
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Figure 3.4: cART treatment of SweAPP N2a cells increases reactive oxygen 
species production.  
ROS levels are increased in EFV or EFV/3TC/AZT treated SweAPP N2a cells: EFV-
treated neuron cells have significantly higher ROS contents (***p < 0.001) after 
incubation for 30 and 60 min than untreated N2a cells. Data represents the ROS 
content in the antiretroviral treatment expressed as % RFU ± standard deviations for 
each group compared to untreated control neuron cells (100%). (***p < 0.001). Note: 60 
min treatment is not shown, but supported data seen at 30 min. 
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Figure 3.5: EFV/3TC/AZT inhibits microglial phagocytosis of Aβ1-42 peptide.  
(A) Primary microglia (1×105 cells/well in 24-well tissue culture plates) were treated with 
aged FITC tagged Aβ1-42 (50 nM) in complete medium for 60 min with antiretroviral 
medications (10uM) combined or singly as indicated, or PBS (control). As a control for 
nonspecifically incorporated Aβ, microglial cells were incubated at 4°C with the same 
treatment followed by DAPI staining. EFV or 3TC/AZT/EFV inhibited microglia-
colocalization by fluorescence microscopy. Green indicates Aβ1-42 positive; blue 
indicates microglia nuclei. Addition of heat inactivated HIV-1 Tat yielded similar results 
as vehicle control (data not shown) (B) Cell supernatants and lysates were analyzed for 
extracellular (top) and cell associated (bottom) FITC-Aβ using a fluorimeter. Data are 
represented as the relative fold of mean fluorescence change (mean ± SD), calculated 
as the mean fluorescence for each sample at 37°C divided by mean fluorescence at 
4°C (n = 6 for each condition presented). One-way ANOVA followed by post-
hoc comparison showed a significant difference between EFV (***p < 0.001) or 
EFV/3TC/AZT (**p < 0.05) but not 3TC or AZT compared to control. 
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Discussion 
Here, we elucidate a potential mechanism whereby EFV may have neurotoxic 
effects via promotion of brain Aβ. Our present study has led to the proposed mechanism 
of neurotoxicity in which EFV promotes an increase in Aβ in vitro and in vivo on both the 
production and clearance fronts via its inhibition of proper MMP resulting in reduced 
ATP stores and thus a high ROS environment in the CNS. It is proposed that EFV 
induced high ROS microenvironments (Fig. 3.4) in the CNS promote BACE-1 APP 
processing ([23]; Fig. 3.1) and also inhibits microglial phagocytic functions (Fig. 3.5; [56, 
57]). These events in turn all promote production of Aβ species. 
 
EFV has been associated with serious adverse reactions, most of which can in 
part be attributed directly or indirectly to dysfunction of mitochondria [22, 24, 25, 30, 31]. 
We found that EFV, or the EFV containing regimen consistently and significantly 
promoted mitochondrial oxidative stress in the form of reduced cellular ATP stores (Fig. 
3.3A) and MMP (Fig. 3.3B), as well as increased release of ROS (Fig. 3.4). These 
observations suggest the mitochondrial stress imparted by this cART regimen is largely 
dependent upon EFV and that 3TC and/or AZT may have some protective effect. 
Indeed there is some evidence that the latter antiretroviral may help to preserve 
cognitive function [45, 46, 53]. 
 
Reactive microgliosis can be associated with the formation of microglial 
phenotypes that are unfavorable to phagocytic activities [57, 58]. ROS are an important 
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signal for cellular activation and proliferation. Over the long term they can lead to 
microglial dysfunction, rendering the phagocytes unable to perform their vital clearance 
functions [57, 58]. This may underlie the reduced microglial phagocytosis of Aβ 
observed in microglia treated with EFV or the EFV containing regimen (Fig. 3.5). 
 
Several lines of epidemiological evidence signal a role for Aβ in HAND 
development while some studies have not yet fully implicated over production of the 
protein as a contributor to HAND. It is known that pathological similarities exist between 
HAND and AD [35-40]. The latter is more so characterized by extracellular deposits of 
Aβ1-42 in the form of plaques and aggregations of microtubule-associated tau yielding 
neurofibrillary tangles (NFT). In contrast, with HIV infection, the plaques are more 
diffuse [36] rather than neuritic [39]. 
 
Cerebrospinal fluid (CSF) biomarkers can mirror pathogenic cerebral amyloid 
deposition. Decreased CSF Aβ1-42 and increased CSF tau can differentiate symptomatic 
AD participants and cognitively normal individuals at high risk for symptomatic AD from 
cognitively normal individuals at low risk for symptomatic AD [59, 60]. In that regard, at 
least some HAND patients have CSF Aβ1-42 values comparable to symptomatic AD 
individuals, that is, reduced [36]. This is salient because reductions in CSF Aβ42 have 
been found in almost all individuals with increased fibrillar amyloid deposition within the 
brain as assessed with positron emission tomography (PET) amyloid binding of N-
methyl-[11C]2-(4-methylaminophenyl)-6-hydroxybenzothiazole (11C-PiB) [61-63]. 
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Likewise, AIDS dementia complex (ADC) patients had significantly decreased CSF Aβ1-
42 and increased total and phospho (t-tau and p-tau respectively) concentrations similar 
to AD [36]. Achim and colleague's (2009) reported increased Aβ by autopsy 
examination, immunoblotting, and microscopy analysis of HIV patients. Specifically, 
cases with HIV encephalitis (HIV-E) were about twice as likely to have amyloid detected 
(72%) than HIV+ patients without HIV-E (38%; [35]). In the same year Clifford and 
colleagues reported Aβ1-42 measurements in CSF of cognitively impaired patients with 
HIV were similarly reduced as in in patients with mild dementia of the Alzheimer type 
(DAT). Normal or slightly depressed CSF tau and p-tau measurements distinguished 
these patients with HAND from patients with DAT [40]. 
 
Further analysis as to why there is low CSF Aβ1-42 in patients with HAND is 
needed. However, there are several reasons which may explain altered Aβ metabolism 
in HIV disease [40] in addition to the data presented in this report. First, HIV-1 
transactivator of transcription (Tat) protein may compete with APP and/or apolipoprotein 
E (an Aβ chaperone) for binding to the low density lipoprotein receptor related protein 
(LRP), thus inhibiting LRP mediated clearance of Aβ from brain interstitial fluid to 
periphery [64]. Second, APP cleavage products (sAPPα and sAPPβ) have been 
reported to be reduced in the CSF of patients with HAND compared to those with DAT 
or HIV-negative controls, with sAPPα (a neurotrophic protein) showing a slight decline in 
the asymptomatic HIV state [65]. 
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In 2010 Ances and colleagues reported cognitively unimpaired HIV+ participants, 
even with low CSF Aβ1-42 (<500 pg/mL), did not have (11)C-PiB parameters suggesting 
brain fibrillar amyloid deposition. It is suggested this dissimilarity between cognitively 
unimpaired HIV+ and preclinical AD may reflect differences in Aβ1-42 production and/or 
formation of diffuse plaques [66]. This same group, in 2012, reported symptomatic AD 
patients were significantly older, had significantly lower CSF Aβ1-42, and had significantly 
higher CSF tau levels than other groups. Regardless of degree of impairment, HIV 
patients did not have increased 11C-PiB [67]. Possible reasons for the absence of 11C-
PiB in HIV patients are: 1) decreased Aβ1-42 production secondary to decreased 
synaptic activity, 2) increased intraneuronal Aβ1-42 deposition that is undetectable 
by 11C-PiB [35]; and/or 3) increased Aβ1-42 brain deposition but in a more diffuse, non-
fibrillar form that is undetectable by 11C-PiB [34, 66]. Future longitudinal examinations 
within older HIV+ participants are required to determine if diffuse or oligomeric forms 
could with time subsequently become fibrillar (11C-PiB positive) deposits [36, 40]. Our 
findings reinforce the importance of understanding the effects of cART on amyloid 
metabolism since EFV could contribute to the neurological complications that are 
associated with HIV infection seen clinically [3-8, 68]. 
 
The current research has several strengths and weaknesses. Regarding the 
former, we observed consistent findings in both in vitro and in vivo model systems in 
that EFV or the EFV containing regimen caused increase amyloidogenic APP 
processing as a function of increased BACE-1 expression and decreased microglial 
clearance of Aβ. Additionally, we find the level of mitochondrial dysfunction imparted by 
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each antiretroviral medication correlates consistently with the increased level of BACE-1 
expression and Aβ production, and the decreased microglial phagocytosis of Aβ 
peptide. Second our results coincide with other reports indicating the mitochondrial 
toxicity of antiretrovirals [24, 25, 30-32], and reports that increased ROS can result in 
increased BACE-1 activity [23]. 
 
This report has limitations as well. First, it describes a mechanism for a subset of 
HAND cases since not all HIV infected individuals are taking EFV or an EFV containing 
regimen. It should be noted that in the present study, we did not investigate the plasma 
or CSF concentrations of antiretrovirals or their metabolites. However, all three drugs 
seem to have good CNS penetration [22, 69, 70], which could support the neurologic 
symptoms noted by others [3, 7, 68]. 
 
In sum, our present work suggests that EFV promotes an increase in Aβ on both 
the production and clearance fronts through oxidative stress. We hypothesize that a 
disrupted MMP with resultant lowered neuronal ATP stores promotes a high level of 
ROS. In turn, this can both promote BACE-1 activity and impair microglial clearance 
mechanisms. If this mouse model translates to the clinical syndrome, then a 
pharmacotherapeutic strategy aimed at opposing the EFV-mediated reduced microglial 
Aβ clearance and/or EFV-mediated neuronal Aβ over production via BACE-1 should be 
beneficial to prevent or treat HAND. 
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CHAPTER FOUR 
EFAVIRENZ DECREASES NEURAL STEM CELL PROLIFERATION4 
 
Introduction 
Soon after infection, human immunodeficiency virus-1 (HIV-1) enters the central 
nervous system (CNS) [1]. Survival times with chronic HIV-1 infection continue to grow, 
and as a result there is an increasingly large number of patients harboring the virus 
within the brain. This may be one contributing factor to the substantial prevalence of 
HIV-associated neurocognitive disorders (HAND) [2]. Past reports have indicated a link 
between HIV-1 with both reduced proliferation of neural stem cells (NSCs) as well as 
reduced neurogenesis [3]. Although HIV does not infect mature neurons, the virus has 
been shown to infect NSCs [4]. It has further been shown that the early HIV-1 infection 
of NSCs may lead to neurocognitive dysfunction [5, 6]. Importantly, NSCs have an 
ability for precise migration to widespread areas of pathology in the brain [7-12]. Thus, 
their reduction may be a contributing factor to HAND, which is marked by chronic 
inflammatory and oxidative injury in the brain [13-15].  
 
 The HIV non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) has been 
a common component of combination antiretroviral therapy (cART) for HIV infection [16, 
																																																								4	Portions of this chapter have been previously published (Jin J, et al., 2016) and are utilized with permission of the 
publisher. 	
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17] and has also been associated with cognitive side effects in both human clinical 
studies and murine models [16, 18, 19]. Studies on human glioma and neuroblastoma 
cell lines as well as rat primary cultures of neurons and astrocytes indicate the 
involvement of EFV in oxidative stress in the CNS [20]. We performed these 
experiments to determine whether EFV could affect NSC proliferation in vitro and in 
vivo. We sought to understand one possible reason why cognitive disorders may occur 
in patients with well-controlled HIV infection who are on EFV therapy [16, 18]. 
 
Results 
EFV Reduces Proliferation of NSCs 
As shown in Figure 4.1A, EFV decreased cell proliferation in a concentration-
dependent manner. At the 5 µM EFV concentration, there were approximately 74% of 
live cells compared to vehicle control (p < 0.05). When EFV concentration was 10 µM, 
live cells were detected at approximately 36% compared to vehicle control treatment 
(p < 0.001). NSC proliferation had a progressive decline as EFV concentration 
increased. The threshold for this decline was the 5 µM concentration of EFV. As shown 
in Figure 4.1B, BrdU incorporation reflected cell proliferation, and nestin was used as an 
NSC marker [21]. The number of double-fluorescent-labeled cells was significantly 
decreased by EFV treatment compared with vehicle control. Vehicle control treatments 
are shown in Figure 4.1B: (a) BrdU, (b) nestin, and (c) merged. EFV treatment (5 µM) is 
shown in (d) BrdU, (e) nestin, and (f) merged; (g) quantified data expressed as 
percentage of double-labeled cells show significant decreases in proliferation in EFV-
treated NSCs (p < 0.001) (Fig. 4.1B). 
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Figure 4.1. EFV reduces proliferation of NSCs.  
Efavirenz (EFV) reduces proliferation of neural stem cells (NSCs). EFV reduces 
proliferation of NSCs by MTT assay. (A) NSCs were treated with a series of 
concentrations of EFV, vehicle control (ctrl), and H2O2 (positive control; 100 µM) for 24 
h. Data are presented as a percentage of EFV treatment over ctrl. Each bar is 
presented as mean ± SEM (*p < 0.05; ***p < 0.001). (B) EFV inhibits bromodeoxyuridine 
(BrdU) incorporation into NSCs as evidenced by immunocytochemistry: after treatment 
consisting of 5 µM of EFV or vehicle control (ctrl) for 24 h, and incubation with BrdU (10 
µM) for 2 h, NSCs were fluorescence stained with BrdU (green) and nestin (red). 
Staining of control treatment is shown in (a) BrdU, (b) nestin, and (c) merged; EFV 
treatment in (d) BrdU, (e) nestin, and (f) merged. Scale bars: 20 µm (a–f). (g) Quantified 
data are expressed as the percentage of double-labeled cells. Data are presented as 
mean ± SEM (***p < 0.001). 
   
	81 
EFV Reduces NSC ATP Stores and MMP 
NSC viability can also be measured by ATP assay. In order to maintain 
biophysiologic function, intracellular ATP levels must remain consistent to maintain 
homeostasis. To determine if EFV could decrease ATP levels in NSCs, as shown in 
Figure 4.2A, they were treated with a series of concentrations of EFV as well as positive 
(H2O2, 100 µM) and vehicle controls for 24 h. Cell lysates were used to measure ATP 
levels, and 5 µM of EFV decreased ATP levels to approximately 78% of vehicle control 
levels (p < 0.05). EFV (10 µM) reduced cellular ATP stores by approximately 57% 
compared to that of vehicle control (p < 0.01) (Fig. 4.2A). Loss of MMP is an event 
associated with oxidative stress and the initiation and activation of apoptosis [22, 23]. 
As shown in Figure 4.2B, NSCs were treated with a series of concentrations of EFV, 
vehicle control, and positive control (H2O2; 100 µM) for 6 h followed by the addition of 
JC-1. In healthy cells, the JC-1 reagent aggregates on intact mitochondrial membranes 
and shows red fluorescence, whereas in apoptotic cells, it exists in monomeric form in 
the cytoplasm showing green fluorescence. The value of red fluorescence (excitation, 
550 nm; emission, 600 nm) divided by green fluorescence (excitation, 485 nm; 
emission, 535 nm) represents MMP. Similar to MTT and ATP assays, the threshold 
concentration was 5 µM of EFV to observe significant effects (Fig. 4.2B). 
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Figure 4.2. EFV reduces NSC ATP stores and MMP.  
EFV reduces NSC adenosine triphosphate (ATP) stores and mitochondrial membrane 
potential (MMP). (A) EFV reduces NSC ATP stores: NSCs were plated in 12-well plates 
with 3 × 105 cells per well and treated with a series of concentrations of EFV, vehicle 
control (ctrl), and H2O2 (positive control; 100 µM) for 24 h. The relevant luminescence 
units (RLU) were measured for each condition. The percentages of treatment over ctrl 
represents intracellular ATP levels of NSCs. Each bar is presented as mean ± SEM 
(*p < 0.05; **p < 0.01). (B) EFV reduces MMP of NSCs: after NSCs were treated with a 
series of concentrations of EFV, vehicle control (ctrl), and H2O2 (positive control; 100 
µM) for 6 h, they were incubated with JC-1 to detect MMP. The ratio of red fluorescence 
(RFU) to green fluorescence (RFU) represents the value of MMP. Data are presented 
as mean ± SEM (*p < 0.05; **p < 0.01). 
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EFV Increases NSC Cytotoxicity and Cell Death 
Because loss of mitochondrial function as examined by JC-1 can lead to 
apoptosis, we also examined EFV-promoted cell death by LDH assay. We again treated 
NSCs with a series of concentrations of EFV, vehicle control, and positive control (cell 
lysis buffer, 30 min) for 24 h (Fig. 4.3). The cell-cultured media were subjected to LDH 
assay. The higher the cell death, the more LDH was released into the media via cell 
membrane damage. EFV promoted toxic responses from NSCs in a concentration-
dependent manner. EFV (5 µM) increased LDH release by nearly twofold compared 
with vehicle control (p < 0.001), while 10 µM of EFV increased LDH release by 
approximately threefold (p < 0.001). 
 
Effect of EFV on p38 MAPK Phosphorylation and Bax Expression 
It has been reported that the phosphorylation of p38 MAPK and Bax activation 
are central antiproliferation inducers of several cell types including stem cells [24-26]. 
This was evidenced by a phosphorylation of p38 in EFV stimulated NSCs. We treated 
these cells with EFV (5 µM; based on the threshold concentration for significant effects 
on NSC mitochondrial function, proliferation, and cytotoxicity) for 1 h and found that 
EFV significantly enhanced phospho-p38 (Ph-p38) expression by Western blot (p < 
0.01) (Fig. 4.4A). To investigate whether p38 MAPK could be correlated with 
upregulated Bax expression, NSCs were further treated with the same concentration of 
EFV for 24 h, which significantly increased Bax expression (p < 0.05) (Fig. 4.4B). 
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Figure 4.3. EFV increases NSC cytotoxicity and cell death.  
EFV increases NSC cytotoxicity and cell death. EFV induces increased cell death of 
NSCs in a dose-dependent manner. Cells were treated with a series of dilutions of EFV, 
vehicle control (ctrl), or assay-positive control (10% cell lysis buffer) for 24 h, and cell 
culture media were subjected to an LDH assay. The value of optical density (OD) at 490 
nm subtracted from the value of OD at 680 nm represents LDH levels. Data are 
presented as mean ± SEM (***p < 0.001). 
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Figure 4.4 EFV increases p38 MAPK phosphorylation and Bax expression.  
EFV increases p38 MAPK phosphorylation and Bax expression. (A) EFV elevates the 
expression of phospho-p38 in NSCs detected by Western blot. NSCs were plated in 24-
well plates for 24 h, treated with 5 µM of EFV or vehicle control (ctrl) for 1 h. Cells were 
then lysed and subjected to Western blot of phospho-p38 (Ph-p38) and total p38. Each 
bar is presented as mean ± SEM (**p < 0.01). (B) EFV elevates expression of Bax from 
NSCs. To detect Bax expression, cells were treated for 24 h with 5 µM of EFV or vehicle 
control (ctrl). Data are presented as mean ± SEM (*p < 0.05). 
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EFV Administration Impairs NSC Proliferation and Induces Apoptosis in the SVZ In Vivo  
To explore NSC proliferation after EFV administration in vivo, C57BL/6J mice at 
8 months of age were injected (IP) with 20 mg/kg of EFV or vehicle control for 4 weeks. 
During the final 5 days, mice additionally received a dose of 50 mg/kg of BrdU daily. 
Quantitative analysis showed that BrdU expression was significantly decreased in the 
EFV treatment group in the sub-ventricular zone (SVZ) compared to the control group (p 
< 0.05) (Fig. 4.5A), indicating an impairment of proliferation. Figure 4.5B exhibits images 
of Dcx staining of the SVZ in the vehicle control group and the EFV group. There was a 
strong trend for the EFV-treated group to have a lower Dcx expression level compared 
to the control group (p=0.08). To uncover a possible underlying effect of EFV that may 
reduce the number of replicating NSCs in vivo, we measured apoptotic marker active 
caspase-3. Results indicated that EFV administration increased the number of active 
caspase-3-expressing cells in the SVZ compared to vehicle control-treated mice (p < 
0.05) (Fig. 4.5C). 
 
Statistical Analysis 
All statistical analyses were performed with SPSS software (version 18.0; IBM, 
Armonk, NY, USA). Data are expressed as mean ± SEM, and results were deemed 
significant when p < 0.05. Variables between groups were determined by independent t-
test or one-way analysis of variance (ANOVA). When significance was achieved, 
analysis of groups was performed using Tukey’s post hoc test. 
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Figure 4.5. EFV administration impairs NSC proliferation and induces apoptosis 
in the SVZ in vivo.  
EFV administration impairs NSC proliferation and induces apoptosis in the SVZ. (A) 
Administration of EFV (20 mg/kg) impairs BrdU incorporation in the SVZ of C57BL/6J 
mice. Mice were administered daily IP injections of EFV or vehicle control (ctrl) for 4 
weeks and BrdU administration for 5 consecutive days prior to euthanization. Sagittal 
sections were stained with BrdU antibody. (a, b) The square marked in (a) represents 
the vehicle control (ctrl)-treated group and is magnified in (b) (n = 7); (c) and (d) the 
square marked in (c) represents EFV treated group and is magnified in (d) (n = 8). Scale 
bar: 20 µm (in micrographs). (e) Quantitative data are represented by the bar graph. 
Each bar is presented as mean ± SEM (*p < 0.05). (B) Administration of EFV shows a 
trend to decrease Dcx expression in C57BL/6J mice in the SVZ. Sagittal sections from 
the same mice were stained by Dcx antibody. (a, b) The square marked in (a) 
represents the vehicle control (ctrl) group and is magnified in (b) (n = 7). (c, d) The 
square marked in (c) represents the EFV treatment group and is magnified in (d) (n = 8). 
Scale bars: 20 µm (in micrographs). (e) Quantitative data are represented in the bar 
graph. Each bar is presented as mean ± SEM (p = 0.08). (C) Administration of EFV 
enhances active caspase-3 expression in the SVZ. Sagittal sections from the same 
mice were stained by active caspase-3 antibody to evaluate apoptosis in the SVZ of 
C57BL/6J mice. (a, b) The square marked in (a) represents the vehicle control (ctrl) 
group and is magnified in (b) (n = 7). (c, d) The square in (c) represents the EFV 
treatment group (n = 8) and is magnified in (d). Scale bars: 20 µm (in micrographs). (e) 
Quantitative data are represented in the bar graph. Data are presented as mean ± SEM 
(*p < 0.05).  
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Discussion 
This study examines the effect of EFV on NSC proliferation in vitro and in vivo. 
Through in vitro experimentation with NSCs, we found that EFV resulted in a 
concentration-dependent decrease in NSC proliferation beginning at a concentration of 
5 µM by MTT assay (Fig. 4.1A). This was further confirmed by immunocytochemistry 
where EFV significantly reduced the incorporation of BrdU into NSCs as identified by 
nestin (Fig. 4.1B).  
 
Our findings also indicated a concentration-dependent decrease in intracellular 
ATP as a result of EFV treatment of NSCs (Fig. 4.2A). Even though studies have shown 
that NSCs function at a lower metabolic rate when compared to other cells, a decreased 
level of intracellular NSC ATP can inhibit the overall process of NSC proliferation [27]. 
Recent studies have shown how various molecules that inhibit the actions of ATP, such 
as tricyclodecan-9-yl-xanthogenate (D609), decrease the rate of proliferation among 
NSCs, therefore opposing the process of proliferation [28]. Moreover, in vitro results 
indicated that EFV lowered NSC MMP (Fig. 4.2B), an event associated with not only 
oxidative stress but also the initiation and activation of apoptosis [22, 23, 29].  
 
LDH is a cytoplasmic enzyme that is released through damaged portions of the 
cellular membrane into the extracellular space [30]. The LDH assay has been shown to 
accurately measure cell death in vitro [31-34]. Increased levels of LDH among the NSCs 
treated with EFV (Fig. 4.3), as studied, are indicative of the apoptotic and/or necrotic 
effect of this drug on NSCs.  
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It has been reported that the p38 MAPK pathway and Bax are central to the 
negative regulation of proliferation of several cell types including stem cells [24, 25]. 
This was shown in our study (Fig. 4.4) by an enhanced phosphorylation of p38 MAPK 
as well as upregulated Bax expression in EFV-stimulated NSCs. These data are in 
accordance with the observed reduced proliferation (Fig. 4.1), mitochondrial function 
(Fig. 4.2), and increased cell death (Fig. 4.3) imparted by EFV. Further, it is in 
agreement with other reports indicating that the increased reactive oxygen species 
(ROS), a result of reduced MMP [35], promotes p38 MAPK phosphorylation [36], which 
in turn promotes Bax activation [26]. 
 
In addition to the in vitro treatment of NSCs, administration of EFV in vivo 
resulted in a decrease in NSC proliferation in C57BL/6J mice (Fig. 4.5). This was 
suggested by significantly decreased BrdU-positive cells in the SVZ (Fig. 4.5A). To 
examine whether the decreased BrdU staining that we observed in the SVZ of these 
mice reflected NSC commitment to the neuronal lineage, we also stained some sections 
with antibodies against Dcx, a neuronal lineage marker expressed in early stages of 
neuronal maturation [37, 38]. Here we found a strong trend toward decreased Dcx 
expression nearing significance (p=0.08) (Fig. 4.5B).  
 
Since our in vitro studies showed increased cell death, cytotoxicity, and Bax 
expression imparted by EFV, we also stained for active caspase-3, which has 
previously been linked with loss of MMP [39]. We found a significant increase in active 
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caspase-3 in the same region (Fig. 4.5C). Thus, our combined data suggest an 
inhibition of NSC proliferation in vitro and in vivo through induction of apoptosis, in effect 
leaving fewer cells present in the SVZ to divide as a result of EFV administration.  
 
Regarding the role of EFV in neurodegeneration and survival of adult neurons, 
oral treatment of rats with EFV for 30 days promoted degenerative changes (decreased 
cellular population, pyknotic nuclei, and presence of microcysts and edema) in the 
lateral geniculate body, suggesting a mechanistic action as a neurotoxin that disrupts 
cellular integrity [40]. Additionally, we demonstrated the ability of EFV to cause signs of 
neurodegeneration in mice in which pathologies characteristic of Alzheimer’s disease 
(AD), such as increased brain β-secretase (BACE-1) expression and enhanced soluble 
amyloid-β (Aβ) generation, were observed [41]. Further, we found that EFV-treated 
SweAPP N2a neurons showed neurodegenerative signs in the form of mitochondrial 
dysfunction and upregulated BACE-1 expression, which promoted Aβ accumulation in 
this model of murine N2a cells transfected with human “Swedish” mutant amyloid 
precursor protein (APP) [41].  
 
There is accumulating data pointing to an interference by EFV with CNS energy 
homeostasis and subsequent neurodegeneration. One investigation exploring this 
showed a significant inhibition of creatine kinase (CK) activity in the hippocampus, 
cerebellum, striatum, and cortex of mice treated with EFV [42]. CK is a catalyst for the 
transfer of the phosphoryl group from phosphocreatine to adenosine diphosphate (ADP) 
to regenerate ATP in the brain and other tissues that consume energy at a high rate. 
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This reduced brain CK activity may partially be responsible for the cognitive 
impairments seen in EFV-treated mice, as suggested by the fact that knockout mice for 
CK in the brain demonstrated cognitive impairment [43].  Importantly, results acquired 
from both animal [44] and human [45] studies have also correlated reduced CK activity 
with neurodegeneration. Additionally, it has been shown that treatment with EFV (10 or 
25 µM) significantly decreased the viability of rat primary cortical neurons [20]. The 
neurodegenerative potential of the EFV metabolite 8-hydroxyefavirenz has also been 
shown in primary rat hippocampal neuronal cultures. In this model, 8-hydroxyefavirenz 
increased entry of extracellular Ca2+, which was mediated largely by L-type voltage-
gated calcium channels [46]. 
 
The SVZ is an important neurogenic niche, and neurons generated in the SVZ 
migrate along the rostral migratory stream to reach the olfactory bulb. Importantly, brain 
injuries stimulate direct migration of new NSCs from the SVZ to the sites of injury [47], 
which may compensate for some of the neurodegenerative changes promoted by EFV 
as noted above. It is thus possible that reduction of NSC proliferation in the SVZ due to 
EFV could contribute to a decline in regenerative actions of these cells, which under 
non-EFV conditions would oppose the chronic injury induced in the brain by HIV itself, 
HIV-activated glial cells, and/or the HIV-secreted proteins such as gp120 and Tat [48]. 
 
It is important to note that EFV has been linked to cognitive dysfunction in 
previous studies [16, 18, 19]. For example, Ciccarelli and colleagues found that EFV is 
associated with cognitive disorders even in asymptomatic HIV-infected patients [18]. 
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Most recently it was also found clinically that long-term EFV treatment was associated 
with detriments to speed of information processing, verbal fluency, and working memory 
[16]. We speculate that EFV-mediated reductions of NSC proliferation may underlie 
some of these reported effects, although no studies to date have examined the exact 
relationship between reduced NSC proliferation and cognitive dysfunction specifically in 
EFV-treated HIV patients.  
 
The current research has several strengths and weaknesses. Regarding the 
former, we observed consistent findings in both in vitro and in vivo model systems in 
that EFV causes decreased NSC proliferation. Additionally, we found the level of 
cellular oxidative stress (reduced ATP stores and MMP) imparted by EFV correlated 
consistently with reduced NSC proliferation and increased cytotoxicity, as well as p38 
MAPK and Bax promotion at the 5 µM concentration. Second, our data coincide with 
other reports indicating that the process of NSC proliferation is highly sensitive to the 
redox balance in that cell proliferation is favored in more reduced environments, and cell 
differentiation is more favored in oxidized environments. As a result, as the levels of 
oxidative stress increase, the rate of proliferation decreases [49]. 
 
This report has limitations as well. First, it describes a mechanism for a subset of 
HAND cases since not all HIV-infected individuals are on EFV therapy. It should also be 
noted that, in the present study, we did not investigate the plasma or cerebrospinal fluid 
(CSF) concentrations of EFV or its metabolites in vivo. However, EFV has good CNS 
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penetration [50], which could support the neurologic symptoms noted by others [16, 18, 
19]. 
 
In sum, our present work suggests that EFV promotes a decrease in NSC 
proliferation, which is correlated with activation of oxidative stress pathways as well as 
Bax and caspase-3 upregulation. It is in accordance with other reports indicating that 
oxidative stress promotes p38 MAPK phosphorylation [36], which in turn promotes Bax 
upregulation [26]. Together these data suggest that EFV is involved in negative 
regulation of NSC proliferation by reducing the number of existing NSCs that are 
available to divide and generate newborn cells. Given that oxidative stress correlated 
with the defects in NSCs, this study also lays the groundwork for future experiments to 
identify possible antioxidant adjunctive treatments to be given with EFV that would 
promote protection of NSCs. 
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CHAPTER FIVE 
FINAL CONSIDERATIONS 
 
Discussion 
The Human Immunodeficiency Virus (HIV) pandemic still persists worldwide. 
What was once seen as a death sentence has now evolved into a chronic disease due 
to the introduction of combination antiretroviral therapy (cART) in 1996. Since this time, 
the life expectancy of HIV-positive patients has dramatically increased. As a result more 
individuals are living longer lives, but there has been an increase in the prevalence of 
certain forms of HIV associated neurocognitive disorder (HAND) within the HIV positive 
population. Up to approximately 50% of HIV-infected patients suffer from some form of 
HAND, yet there is not a clear understanding of the cause of HAND, nor are there any 
current preventive or therapeutic agents [1].  
 
Clinically, there can be changes in cognition (learning, memory, attention, and 
executive function), motor coordination (psychomotor slowing, hypertonia) and 
behavioral changes (apathy) [2-4]. A major study linking Alzheimer’s Disease (AD)-like 
pathology in HIV-positive patients showed beta amyloid (Aβ) plaques formed in greater 
amounts in HIV-positive patients who died between 30-69 years of age compared to 
HIV-negative age-matched patients [5]. In fact, epidemiological data suggests that 
persons living with HIV are at elevated risk of developing AD-like type brain pathology 
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[5-8].  Aβ generation and aggregation are key events in AD, which leads to neurotoxicity 
and CNS inflammation [9-11].  
 
There has been substantial evidence showing the negative impacts that both the 
HIV virus and its proteins (tat, gp120) can have on the CNS. However, the potential 
early onset of AD-like pathology in the HIV population can be induced by several other 
factors. One such factor may be certain components of cART, a combination of several 
drugs that have drastically decreased the morbidity and mortality rates as a result of 
their ability to efficiently suppress the HIV viral load [12, 13].  Despite these results, few 
research studies have focused on the role these life long cART medications may play in 
its pathogenesis.  
   
Several factors may contribute to HAND pathology such as: poor cART 
adherence, emergence of resistant viral species, or residual viral DNA in the central 
nervous system (CNS) [14]. With the prevalence of milder forms of HAND increasing 
and the mechanism still unexplained, it is crucial to look at the impact of antiretrovirals 
(ARVs) on the CNS. Pharmacokinetic studies suggest that many ARVs have limited 
penetrance into the CNS and that ARV concentrations are low in the cerebrospinal fluid 
(CSF) and parenchyma. However, it is important to consider that the blood brain barrier 
(BBB) is compromised by the viral proteins or concomitant factors that could possibly 
result in higher concentrations of ARVs within the CNS of HIV-positive patients [14]. In 
addition, efaviranz (EFV) is among the best of all ARVs with a score of 3 out of 4 in the 
CNS Penetration Effectiveness Rank, which is a measure of ARV penetration into the 
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CNS [15]. The possible impact of EFV in the CNS of HIV-positive patients is therefore 
clinically relevant and can be another potential contributor to HAND pathology and its 
neuropsychiatric symptomology. 
 
While cART increases patient lifespan, it may contribute to CNS toxicity. The 
prospect of ARVs contributing to or inducing HAND is not well studied, but our lab and 
other research groups show that certain ARVs induce oxidative stress and neuronal 
damage in the CNS [14, 16-20].   Furthermore, ARVs are associated with potentially 
serious side effects. EFV, prescribed worldwide since 1998, has clinical CNS side 
effects including: neurocognitive decline, hallucinations, psychosis, abnormal dreams, 
and insomnia [21-24]. In mice, EFV affected anxiety and cognitive performance [25]. 
Long term use of EFV has also been shown to correlate with the worsening of 
neurocognitive functioning including speed of information processing, verbal fluency, 
and working memory [26]. Our studies originality is based on the fact that there is 
limited research that focuses on the importance of cART drugs in pathology that may 
promote HAND. The central focus of our study was to determine the effect of the 
commonly prescribed ARV drug (EFV) and its roles in HAND pathogenesis in terms of 
oxidative stress, Aβ production/clearance, and neurogenesis. 
 
 As aforementioned, a key element of HAND pathology may parallel that of AD. 
Significant Aβ deposition in the brains of HIV infected patients was observed [5], and it 
has been suggested that Aβ deposition is a possible pathological feature of HIV 
infection [6, 27]. Chapter 3 explores the effect of the non-nucleoside reverse 
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transcriptase inhibitor (NNRTI), EFV, on Aβ accumulation. The major finding and 
conclusion of this work is that EFV is neurotoxic in vitro and in vivo by increasing Aβ 
accumulation. As ARVs are often given in a regimen, we first evaluated the 3-drug 
regimen of zidovudine (AZT), lamivudine (3TC) and EFV. We have shown that EFV 
treatment confers the most toxicity of the 3-drug regimen prescribed (compared to AZT 
and 3TC) [20]. This was extrapolated from our data that showed EFV: 1) increased Aβ 
production; and 2) decreased Aβ clearance. This was then further supported by EFV 
promotion of oxidative stress in the form of decreased mitochondrial membrane 
potential (MMP) and adenosine triphosphate (ATP), with increased reactive oxygen 
species (ROS) production. This work, combined with that of other labs, shows that EFV 
has significant neurotoxic effects particularly on mitochondrial dysfunction [17, 19, 20]. 
This increase in ROS production leads to the activation of beta secretase-1 (BACE-1), 
an enzyme involved in amyloidogenic APP processing, and ultimately promotes 
neurodegenerative and AD-like pathology (Chapter 3) [28, 29]. Considering that EFV is 
the main player in toxicity within the cART regimen, this presented the opportunity to 
explore other neurodegenerative characteristics the drug may have. 
 
As stated earlier HAND patients displayed cognitive dysfunction including, but 
not limited to, deficits in learning, memory, attention, executive function [2-4]. The 
hippocampus plays a major role in learning and memory. It also is extremely susceptible 
to inflammatory insults that affect the brain. Adult neurogenesis has only recently been 
accepted to occur postnatally. However, the importance of adult neural stem cells 
(NSCs) has taken the interest of the neuroscience field due to the important roles they 
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may play in learning, memory, and repair of damaged areas of the brain. Therefore, we 
wanted to elucidate if EFV toxicity may also have further effects on neurogenesis 
(Chapter 3). The conclusions drawn from the study on neurogenesis did in fact show 
negative effects on NSC proliferation [30].  These experiments found that EFV in vitro 
and in vivo: 1) reduced proliferation of NSCs; 2) promoted increased mitochondrial 
dysfunction; and 3) increased cytotoxicity and cell death. Evaluating further, it was 
shown that there was an increase in p38 phosphorylation and Bax, which suggests a 
mechanism underlying the observed cell death and reduced NSC proliferation (Chapter 
4) [31, 32]. Considering the side effects often reported (e.g., cognitive decline, sleeping 
disruptions and hallucinations); the impact of EFV on the CNS at the cellular and 
molecular level is not surprising. This research has nevertheless characterized a 
possible EFV mediated mechanism that could affect the CNS negatively, especially 
over the course of long term treatment.  
 
Due to the results of these experiments, it is important to begin looking to the 
future for improvements in ARV therapy. In April 2015, the Department of Health and 
Human Services (DHHS) changed the recommended regimen for cART naïve patients 
[33]. The first line regimen, that included efavirenz (EFV), is now adjusted to consist of a 
new generation of drugs classified as integrase inhibitors (InSTIs) and protease 
inhibitors (PIs). The InSTIs include dolutegravir (DTG), elvitegravir (EVG), raltegravir 
(RAL), while darunavir (DRV) is a PI. One of these InSTIs or the PI is given in different 
combinations with 2 nucleoside reverse transcriptase inhibitors (NRTIs) to complete the 
3 drug cART regimen [33].  
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InSTIs are a more recent drug class. InSTIs inhibit the strand transfer activity of 
HIV integrase in the absence of an effect on 3′ end processing [34]. DTG has been 
available since 2013 through Fast Track approval from the Food and Drug 
Administration (FDA). It has been approved for cART naïve patients as well as those 
who may have been on other drug regimens. With limited time to evaluate CNS effects, 
DTG-containing regimen was shown to increase the risk of insomnia compared to an 
EFV-containing regimen. Overall however, DTG has been reported to be well tolerated 
with very few side effects, of which the most common included the aforementioned 
trouble sleeping, as well as tiredness, and headaches [35-42]. RAL has been available 
for use since 2007 for patients that were already on some form of cART therapy; 
however, in 2009, it was made available for cART-naïve patients. In a case report of 
four patients RAL was said to worsen depression after initiation of treatment [43], while 
there have also been cases of insomnia induced by RAL [44-46]. ELV was approved by 
FDA in 2012. Currently there are no reports on CNS effects. However, the most 
common side effect of ELV is reported to be diarrhea [47, 48].	
 
PIs block proteolysis of the viral polyprotein, which is required to produce 
infectious virus particles through cleaving the viral precursors. DRV was approved by 
FDA in 2006. While there have not been a large amount of CNS side effects reported, 
some of the common side effects reported for patients taking DRV-containing regimens 
include diarrhea, nausea, rash, headache, stomach pain, and vomiting [49-51].  
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In general InSTIs are highly effective and have few adverse effects including no 
significant drug-drug interaction (specifically CYP 3A4) [33].  Even more so, InSTIs have 
been shown to be better tolerated compared to PIs [33, 52]. Thus it is highly 
recommended by the DHHS to select an InSTI for most patients. However, DRV does 
have an advantage. If resistance test results are not readily available prior to treatment 
or adherence is uncertain, DRV (the PI) has a high genetic barrier to resistance, and 
low rate of treatment-emergent resistance. DTG has also been shown to be beneficial in 
this population of individuals [33].  
 
When looking at the increasing numbers of individuals reporting CNS side effects 
due to EFV, as well as results such as our own work showing the potential negative 
consequences of EFV on the CNS, it was expected that the regimen would be altered. 
So far, the research in our lab has focused on the effects of EFV on the CNS and the 
possibility of it being a contributor to HAND. EFV increased Aβ accumulation (Chapter 
3) and decreased neural stem cell (NSC) proliferation (Chapter 4). Furthermore, EFV 
has been extensively researched for mitochondrial dysfunction. It has been shown to 
decrease cell viability and increase the release of reactive oxygen species (ROS) [18-
20]. In future studies, due to the changes in the first line of regimen in the U.S., we 
would aim to elucidate whether the new recommended drugs (DTG, RAL, ELV, and 
DRV) had neurotoxic effects that may lead to Aβ accumulation, increased oxidative 
stress or decreased NSC proliferation. The direction for this project would include 
evaluating in vivo studies especially considering the newer drugs have been reported to 
be more tolerable than EFV. 
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Unfortunately, while the DHHS has changed their guidelines, the impact of HIV 
has not changed for developing nations around the world that still have EFV as a first 
line recommended drug. UNAIDS estimated of the 35 million people infected by HIV at 
the end of 2013, about 24.7 million live in sub-Saharan Africa; accounting for more than 
69% of persons living with HIV. In the US alone, 1.2 million people are infected with HIV 
as of 2013, which accounts for only 3% of all HIV cases in the world [53]. These 
statistics are important when looking at the continued changes occurring with cART 
regimens. Within each region or country there are specific recommendations that 
govern treatment provided to individuals infected with HIV. In the United States, this is 
governed by the DHHS. These laws change rapidly as new drugs are created and 
passed by FDA for treating HIV patients. On a global scale however, the World Health 
Organization (WHO) sets guidelines in order place in order to explore the needs of 
those countries that may not be able to have access to newer recommended drugs as 
they are updated.  In most regions affected by HIV, such as sub-Saharan Africa and 
Asia, they follow the 2013 WHO guidelines [54].  Notably, the WHO guidelines were 
again revised in 2016, however EFV still remained a first like ARV recommendation 
[55]. Therefore, further studies to understand other possible negative CNS effects of 
EFV may be needed.   
 
It is possible that EFV may have an impact on tau hyperphosphorylation, a 
characteristic seen in both HAND and Alzheimer’s patients. In our review [56], we 
examined human studies of HIV positive patients measuring p-tau (phosphorylated tau) 
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or t-tau (total tau) in cerebrospinal fluid (CSF) or via post-mortem brain 
immunohistochemistry. Several studies show that p-tau, t-tau, or both were increased in 
patients [7, 57-59]. In a more recent study, Cysique and colleagues showed that 
increased CSF p-tau levels were associated with current neurocognitive impairment in 
the majority of their HIV infected study participants [60].  
 
It would be advantageous to explore adjunctive therapies that can reduce the 
toxicity of EFV for those currently on the drug regimen. cART has limited capability in 
CNS efficacy, it cannot directly ameliorate HAND pathology, and has in some cases 
shown negative effects on cognition. Consequently, alternative methods are needed for 
HIV and HAND treatment. Because the largest population of HIV-positive individuals 
live in developing countries, researchers are exploring natural antiviral remedies. These 
remedies would not only be cost effective, but may also display an equal or greater 
efficacy than the currently approved cART medications. Recent reviews and 
experiments have analyzed natural extracts (i.e., flavonoids, phenols, and terpenoids) 
that have the ability to affect the virus at all levels of its life cycle [61-67]. These extracts 
also show improvements in CNS toxicity in regard to one or more of the following: ROS, 
NOS, Aβ, tau, neurogenesis and other degenerative pathologies [68-75]. Each of these 
improvements are also pathological characteristics used to explain the possible 
underlying mechanisms of HAND development and can be observed despite cART 
treatment in many persons living with HIV.  
 
As an example, the flavonoid Quercetin is found in Thevetia peruviana (also 
referred to as yellow oleander or lucky nut): a plant found in Central America and the 
	109 
Caribbean. Quercetin has been shown to have HIV integrase inhibitory activity [76]. 
Quercetin also had antioxidant and anti-inflammatory effects, providing possible roles in 
ischemic brain injuries and neurodegenerative disease through protection against 
oxidative stress. It ameliorated brain damage and provided neuroprotection in the 
subarachnoid hemorrhage mouse models [77]. Quercetin was also shown to 
significantly reduce hyperphosphorylation of tau, Aβ1-40 and Aβ1-42 levels, and a 
decrease BACE-1-mediated cleavage of APP [78].  With more directed research in this 
area, it could open new possibilities, not only for the prophylaxis or treatment of HAND 
pathology but for anti-HIV treatment in general.  
 
The overall limitation of this study is that it may only apply to a subset of HIV 
patients who would have EFV in their drug regimen. Indeed, we have not explored all 
drug regimens and the impact on the CNS. Because of the strong previous 
recommendations of EFV as a part of a first line treatment regimen, a majority of 
persons living with HIV would have more than likely been prescribed an EFV containing 
regimen in the course of the HIV therapy.  
 
Conclusion 
In the course of our research, I have been able to visit and work in 2 of the high 
HIV prevalent countries in the world, Malawi (visited in 2016) and Kenya (visited in 
2013). To date, there is a high prevalence of adults infected with HIV in both in Malawi 
and Kenya [79, 80]. While working with either the Development Initiative Network 
(Malawi) or Centers of Disease Control and Prevention/ Kenya Medical Research 
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Institute  (CDC/KEMRI, Kenya), it was apparent the need not only for our research, but 
the improvements needed for ARV therapy affecting the CNS as a whole. In both 
countries there was an under-diagnosis of most neurological diseases due to resource 
limitations. This includes but is not limited to: 1) the inability to have access to 
diagnostic tools such as magnetic resonance imaging (MRI) and computerized 
tomography (CT) scan; 2) lack of specialized personnel (i.e. there are .03 neurologists 
for 100,000 persons in Kenya in comparison to 2.96 in a developed nation such as the 
United States [81]), and finally 3) the focus on the more life threatening prognoses (such 
as death) in high prevalent diseases like malaria, TB and HIV. This is not uncommon for 
developing countries, in which Malawi and Kenya are ranked among the poorest 
countries. It is therefore crucial to begin to set in place accessible treatment options for 
those affected by CNS complications within regions most affected by HIV. 
 
AZT was the first drug approved by the Food and Drug Administration (FDA) to 
treat HIV in 1987, with a record-breaking approval of less then 4 months via priority 
review [82]. While the FDA has become more aware of rapid drug approval through 
various methods such as fast-track and break-through drug therapy protocols, HIV 
drugs are still rapidly approved due to the need to control viral loads, which ultimately 
saves lives [83]. However, this may limit the ability to explore more long term effects of 
these drugs, such as EFV, that may be present after chronic use. This project has 
therefore added to the knowledge base of the role EFV may have in HAND 
development, as well as identified mechanisms by which EFV may result in CNS side 
effects. Our findings suggest there may be a neurotoxic consequence for patients on 
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EFV therapy. This underlying neurotoxicity stems from mitochondrial dysfunction and 
ROS production, in turn leading to Aβ accumulation and a reduction in NSC 
proliferation. The culmination of these results suggests that EFV may have play a role in 
pathologies that could promote HAND and measures may be needed to improve the 
future of cART therapy as it relates to neurotoxicity. 
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